Onsite
MEETING GUIDE
2017 AAD Annual Meeting
Orlando, Florida
March 3-7, 2017
ORANGE COUNTY CONVENTION CENTER
Experience AAD in
ORLANDO
Look inside to find key information about the Annual Meeting
10
1O GREAT WAYS TO
EXPERIENCE IT ALL
Annual Meeting essentials
33
EXHIBITORS
• Alphabetically
• By booth
• By category
56
FOOD AND FUN
Your guide to Orlando
attractions and restaurants
Download the mobile app in the App Store for scientific program information, as well as the most-up-date
information about the Annual Meeting.
BO VIS
OT IT US
H AT
12
75
PEELS ARE
OUR FORTE
P
Organic Aloe Vera
Gel Base
Detox
Complex
Energy
Complex
Plant-derived
Stem Cell Technology
Protection
Complex
Botanical Lightening
Complex
EXCLUSIVELY FROM IMAGE SKINCARE
www.imageskincare.com
|
1.800.796.7546
|
[email protected]
|
WELCOME TO THE 2017 AAD ANNUAL MEETING
In this issue
GREETINGS from the
AAD president
4
WELCOME from the Scientific Assembly
Committee chair
6
EDUCATION
27
28
Poster information
Educational highlights
EXHIBIT HALL
32
33
38
43
Exhibit Hall floor plan
Exhibitors alphabetically
Exhibitors by booth number
Exhibitors by product category
MAPS
48Orange County Convention 50
Center floor plans
Hotel floor plans
CITY GUIDE
52 Orlando by the numbers
53 Safety tips
56Fun and food in Orlando
.
10
10 GREAT WAYS
to experience the Annual Meeting
20
American Academy
of Dermatology
930 E. Woodfield Road
Schaumburg, IL 60173
(866) 503-7546
Orange County Convention Center
9800 International Drive
Orlando, FL 32819 • occc.net
Publishing partner for AAD
Ascend Integrated Media LLC
6710 W. 121st St., Suite 100
Overland Park, KS 66209 • (913) 469-1110
The official American Academy of Dermatology
Experience AAD in Orlando guide is published by
AAD as an exclusive service to meeting attendees.
While every effort is made to ensure accuracy,
AAD makes no warranties, expressed or implied,
related to the information. Information contained
herein is subject to change without notice. No part
of this publication may be reproduced, stored or
transmitted without written permission from AAD.
© 2017. All rights reserved.
2
Experience AAD in Orlando
DAILY
highlights
NOTES
18
Honors & awards
A place for notes 60 • Advertiser index 64
Now Approved!
Connect • the • dots to learn more
Entrance to
convention hall
AAD food court
at booth #2589
PP-CRI-USA-0200 © 2017 Pfizer Inc. All rights reserved. Printed in USA/January 2017
WELCOME TO THE 2017 AAD ANNUAL MEETING
WELCOME
from the president
Members deserve the best
Welcome to Orlando, the land of Magic — the Magic Kingdom, the NBA
Magic, and the ‘magical’ dermatology world of the 2017 AAD Annual
Meeting.
The locale will be lush and friendly and the meeting site — the Orange County Convention
Center — will be grand. The Scientific Assembly Committee (SAC) and its program
chair, Allison Vidimos, MD, have organized a truly outstanding program with much
to offer, including interactive sessions, live demonstrations, MOC-directed sessions, a
member-directed ‘Hot Topics’ afternoon, many new and smaller sessions, an international
symposium day, and several ‘What’s New’ sessions — all of which will broaden and
enhance the educational opportunities for members.
ABEL TORRES, MD
President, American Academy
of Dermatology
The meeting promises a lot, and members deserve the best. The AAD meetings team
has arranged the following to complement the overall experience: networking lounges
throughout the convention center, an expanded AAD Resource Center, and unopposed
exhibit hours to investigate new products and services, all coupled with the opportunity to
meet friends and colleagues. And, of course, given the time and inclination, venture out
and explore some of the extracurricular activities and sites nearby, including Disney World
and Epcot, Universal Studios, and spring training baseball. The meeting will be special,
hopefully even magical, and the absolute best the Academy has to offer, set in an attractive
area with the promise of good weather and Mickey and Minnie nearby. Can’t ask for more
than that!
4
Experience AAD in Orlando
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
WELCOME TO THE 2017 AAD ANNUAL MEETING
WELCOME
from the committee chair
More than 375 sessions equal
truly great content
I’m pleased to be the Scientific Assembly Committee Chair during such an
exciting time in dermatology.
There are many medical meetings that offer good educational material, but as I review this
program with more than 375 available sessions chosen by the Scientific Assembly Committee, I
have to say this is truly great content.
The meeting has continued to grow, with more hands-on offerings, including sessions for
lasers, scar revision, practical anatomy for dermal fillers, nail surgery, innovative suture
techniques, electrosurgery and cryosurgery, wound closures, and varicose and telangiectatic
veins. Additional interactive sessions on “Medication Management,” “The Difficult Patient,”
“Breaking Bad News,” and “Total Body Skin Exam” are also slated.
ALLISON VIDIMOS, MD
Chair of the AAD
Scientific Assembly Committee
Like many years before, Sunday’s Plenary session will again be one of the main attractions of
the Annual Meeting, and will include numerous icons from across the specialty on topics of
broad interest.
• Carrie L. Kovarik, MD, will cover both the challenges and improvements that dermatologists
will encounter as new models of health care delivery systems continue to evolve in her talk,
“Telemedicine and the Future of Medicine.”
• Christine Léauté-Labrèze, MD, will present “Propranolol in Infantile Hemangiomas:
A Successful Drug Repurposing.”
• Boris C. Bastian, MD, PhD, will share recent research on the molecular evolution of
melanomas and a summary on the molecular taxonomy of melanocytic neoplasms in his
lecture titled, “How Moles Become Cancer.”
• Joel M. Gelfand, MD, MSCE, will present “Getting to the Heart (and other Co-morbidities)
of Psoriasis.”
• Our guest speaker, RADM Jordan Tappero, MD, MPH — director of the Division of
Global Health Protection, Center for Global Health, Centers for Disease Control and
Prevention — will wrap up the Plenary with his talk on “The West African Ebola Epidemic
and the Global Health Security Agenda.”
“Hot Topics,” “Late Breaking Research,” live demonstrations, and so many other new and
returning symposiums, workshops, and courses highlight the expansive list of offerings.
What’s more, we have expanded the number of sessions eligible for MOC self-assessment
credit — including all the hands-on and Audience Response System sessions, in addition to the
traditional question-based sessions. Please enjoy the opportunity to choose an enriching,
up-to-date, and comprehensive educational program.
6
Experience AAD in Orlando
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
See for yourself with once-daily
ACZONE Gel 7.5%.
®
VISIT ALLERGAN BOOTH 2253 TO LEARN MORE
INDICATIONS AND USAGE
ACZONE ® (dapsone) Gel 7.5% is indicated for the topical
treatment of acne vulgaris in patients aged 12 years
and older.
IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Hematological Effects
Methemoglobinemia: Cases of methemoglobinemia
with resultant hospitalization have been reported
post marketing in association with twice-daily
dapsone gel 5% treatment. Patients with glucose-6phosphate dehydrogenase deficiency or congenital or
idiopathic methemoglobinemia are more susceptible
to drug-induced methemoglobinemia. Avoid use
of ACZONE ® Gel 7.5% in patients with congenital or
idiopathic methemoglobinemia.
Signs and symptoms of methemoglobinemia may be
delayed some hours after exposure. Initial signs and
symptoms of methemoglobinemia are characterized
by a slate-gray cyanosis seen in, eg, buccal mucous
membranes, lips, and nail beds. Advise patients to
discontinue ACZONE ® Gel 7.5% and seek immediate
medical attention in the event of cyanosis.
Dapsone can cause elevated methemoglobin levels,
particularly in conjunction with methemoglobininducing agents.
Hemolysis: Oral dapsone treatment has produced
dose-related hemolysis and hemolytic anemia.
Individuals with glucose-6-phosphate dehydrogenase
(G6PD) deficiency are more prone to hemolysis with the
use of certain drugs. G6PD deficiency is most prevalent in
populations of African, South Asian, Middle Eastern, and
Mediterranean ancestry.
In clinical trials, there was no evidence of clinically
relevant hemolysis or hemolytic anemia in subjects
treated with topical dapsone. Some subjects with G6PD
deficiency using dapsone gel 5% twice daily developed
laboratory changes suggestive of hemolysis.
Discontinue ACZONE ® Gel 7.5% if signs and symptoms
suggestive of hemolytic anemia occur. Avoid use of
ACZONE ® (dapsone) Gel 7.5% in patients who are taking
oral dapsone or antimalarial medications because of
the potential for hemolytic reactions. Combination of
ACZONE ® Gel 7.5% with trimethoprim/sulfamethoxazole
(TMP/SMX) may increase the likelihood of hemolysis in
patients with G6PD deficiency.
Peripheral Neuropathy
Peripheral neuropathy (motor loss and muscle weakness)
has been reported with oral dapsone treatment. No
events of peripheral neuropathy were observed in clinical
trials with topical dapsone treatment.
Skin Reactions
Skin reactions (toxic epidermal necrolysis, erythema
multiforme, morbilliform and scarlatiniform reactions,
bullous and exfoliative dermatitis, erythema nodosum,
and urticaria) have been reported with oral dapsone
treatment. These types of skin reactions were not
observed in clinical trials with topical dapsone treatment.
ADVERSE REACTIONS
The most common adverse reactions of ACZONE® Gel 7.5%
are dryness and pruritus at the application site.
Methemoglobinemia has been identified during
postmarketing use of topical dapsone.
DRUG INTERACTIONS
Topical application of dapsone gel followed by benzoyl
peroxide in patients with acne vulgaris may result in a
temporary local yellow or orange discoloration of the skin
and facial hair.
Please see Brief Summary of ACZONE ® Gel 7.5% full
Prescribing Information on following page.
© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners. AczoneHCP.com ACZ104709 01/17 170124
ACZONE ® (dapsone) Gel 7.5%
BRIEF SUMMARY—PLEASE SEE THE ACZONE ® PACKAGE INSERT FOR FULL
PRESCRIBING INFORMATION
INDICATIONS AND USAGE
ACZONE ® Gel 7.5% is indicated for the topical treatment of acne vulgaris in
patients aged 12 years and older.
DOSAGE AND ADMINISTRATION
For topical use only. Not for oral, ophthalmic, or intravaginal use. After the
skin is gently washed and patted dry, apply approximately a pea-sized
amount of ACZONE ® Gel 7.5% in a thin layer to the entire face once daily.
In addition, a thin layer may be applied to other affected areas once
daily. Rub in ACZONE ® Gel 7.5% gently and completely.
If there is no improvement after 12 weeks, treatment with ACZONE ®
Gel 7.5% should be reassessed.
CONTRAINDICATIONS
None.
WARNINGS AND PRECAUTIONS
Hematological Effects
Methemoglobinemia
Cases of methemoglobinemia, with resultant hospitalization, have been
reported post marketing in association with twice-daily dapsone gel, 5%,
treatment. Patients with glucose-6-phosphate dehydrogenase deficiency
or congenital or idiopathic methemoglobinemia are more susceptible to
drug-induced methemoglobinemia. Avoid use of ACZONE ® Gel 7.5% in
those patients with congenital or idiopathic methemoglobinemia.
Signs and symptoms of methemoglobinemia may be delayed some
hours after exposure. Initial signs and symptoms of methemoglobinemia
are characterized by a slate-gray cyanosis seen in, eg, buccal mucous
membranes, lips, and nail beds. Advise patients to discontinue ACZONE ®
Gel 7.5% and seek immediate medical attention in the event of cyanosis.
Dapsone can cause elevated methemoglobin levels particularly in
conjunction with methemoglobin-inducing agents (see Drug Interactions).
Hemolysis
Oral dapsone treatment has produced dose-related hemolysis and
hemolytic anemia. Individuals with glucose-6-phosphate dehydrogenase
(G6PD) deficiency are more prone to hemolysis with the use of certain
drugs. G6PD deficiency is most prevalent in populations of African, South
Asian, Middle Eastern, and Mediterranean ancestry.
In clinical trials, there was no evidence of clinically relevant hemolysis
or hemolytic anemia in subjects treated with topical dapsone. Some
subjects with G6PD deficiency using dapsone gel, 5%, twice daily
developed laboratory changes suggestive of hemolysis (see Use in
Specific Populations).
Discontinue ACZONE ® Gel 7.5% if signs and symptoms suggestive of
hemolytic anemia occur. Avoid use of ACZONE ® Gel 7.5% in patients
who are taking oral dapsone or antimalarial medications because of
the potential for hemolytic reactions. Combination of ACZONE ® Gel 7.5%
with trimethoprim-sulfamethoxazole (TMP/SMX) may increase the
likelihood of hemolysis in patients with G6PD deficiency (see Drug
Interactions).
Peripheral Neuropathy
Peripheral neuropathy (motor loss and muscle weakness) has been
reported with oral dapsone treatment. No events of peripheral neuropathy
were observed in clinical trials with topical dapsone treatment.
Skin Reactions
Skin reactions (toxic epidermal necrolysis, erythema multiforme,
morbilliform and scarlatiniform reactions, bullous and exfoliative
dermatitis, erythema nodosum, and urticaria) have been reported
with oral dapsone treatment. These types of skin reactions were not
observed in clinical studies with topical dapsone treatment.
ADVERSE REACTIONS
Clinical Studies Experience
Because clinical trials are conducted under widely varying conditions,
adverse reaction rates observed in the clinical trials of a drug cannot be
directly compared to rates in the clinical trials of another drug and may
not reflect the rates observed in practice.
A total of 2161 patients were treated with ACZONE ® Gel 7.5% for 12 weeks in
2 controlled clinical studies. The population ranged in age from 12 to 63
years, and was 56% female and 58% Caucasian.
Adverse drug reactions that were reported in at least 0.9% of subjects
treated with ACZONE ® Gel 7.5% included:
Adverse Reactions Occurring in at Least 0.9% of Subjects With
Acne Vulgaris in 12-Week Controlled Clinical Trials
ACZONE ® Gel 7.5%
(N = 2161)
Vehicle
(N = 2175)
Application-site
Dryness
24 (1.1%)
21 (1.0%)
Application-site
Pruritus
20 (0.9%)
11 (0.5%)
Experience With Oral Use of Dapsone
Although not observed in the clinical trials with topical dapsone, serious
adverse reactions have been reported with oral use of dapsone, including
agranulocytosis, hemolytic anemia, peripheral neuropathy (motor loss
and muscle weakness), and skin reactions (toxic epidermal necrolysis,
erythema multiforme, morbilliform and scarlatiniform reactions, bullous
and exfoliative dermatitis, erythema nodosum, and urticaria).
Postmarketing Experience
The following adverse reactions have been identified during
post-approval use of topical dapsone. Because these reactions are
reported voluntarily from a population of uncertain size, it is not always
possible to reliably estimate their frequency or establish a causal
relationship to drug exposure.
Methemoglobinemia has been identified during postmarketing use of
topical dapsone (see Warnings and Precautions).
DRUG INTERACTIONS
No formal drug-drug interaction studies were conducted with ACZONE ®
Gel 7.5%.
Trimethoprim-Sulfamethoxazole
A drug-drug interaction study evaluated the effect of the use of
dapsone gel, 5%, in combination with double-strength (160 mg/800 mg)
trimethoprim-sulfamethoxazole (TMP/SMX). During co-administration,
systemic levels of TMP and SMX were essentially unchanged, however,
levels of dapsone and its metabolites increased in the presence of
TMP/SMX. The systemic exposure from ACZONE ® Gel 7.5% is expected to be
about 1% of that from the 100 mg oral dose, even when co-administered
with TMP/SMX.
Topical Benzoyl Peroxide
Topical application of dapsone gel followed by benzoyl peroxide in
patients with acne vulgaris may result in a temporary local yellow or
orange discoloration of the skin and facial hair.
Drug Interactions With Oral Dapsone
Certain concomitant medications (such as rifampin, anticonvulsants,
St. John’s wort) may increase the formation of dapsone hydroxylamine,
a metabolite of dapsone associated with hemolysis. With oral dapsone
treatment, folic acid antagonists, such as pyrimethamine, have been
noted to possibly increase the likelihood of hematologic reactions.
Concomitant Use With Drugs That Induce Methemoglobinemia
Concomitant use of ACZONE ® Gel 7.5% with drugs that induce
methemoglobinemia such as sulfonamides, acetaminophen, acetanilide,
aniline dyes, benzocaine, chloroquine, dapsone, naphthalene, nitrates
and nitrites, nitrofurantoin, nitroglycerin, nitroprusside, pamaquine,
para-aminosalicylic acid, phenacetin, phenobarbital, phenytoin,
primaquine, and quinine may increase the risk of developing
methemoglobinemia (see Warnings and Precautions).
USE IN SPECIFIC POPULATIONS
Pregnancy
Teratogenic Effects: Pregnancy Category C
There are no adequate and well-controlled studies in pregnant women.
ACZONE ® Gel 7.5% should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus. Dapsone has been shown
to have an embryocidal effect in rats and rabbits when administered
orally during the period of organogenesis in doses of 75 mg/kg/day
and 150 mg/kg/day, respectively (approximately 1400 and 425 times,
respectively, the systemic exposure that is associated with the maximum
recommended human dose [MRHD] of ACZONE ® Gel 7.5% based on
AUC comparisons). These effects may have been secondary to
maternal toxicity.
Nursing Mothers
Although systemic absorption of dapsone following topical application
of ACZONE ® Gel 7.5% is minimal relative to oral dapsone administration,
it is known that dapsone is excreted in human milk. Because of the
potential for oral dapsone to cause adverse reactions in nursing infants, a
decision should be made whether to discontinue nursing or to discontinue
ACZONE ® Gel 7.5%, taking into account the importance of the drug to
the mother.
Pediatric Use
Safety and efficacy was evaluated in 1066 subjects aged 12 to 17 years
treated with ACZONE ® Gel 7.5% in the clinical trials. The safety profile for
ACZONE ® Gel 7.5% was similar to the vehicle control group. Safety and
effectiveness of ACZONE ® Gel 7.5% have not been established in pediatric
patients below the age of 12 years.
Geriatric Use
Clinical trials of ACZONE ® Gel 7.5% did not include sufficient numbers of
subjects aged 65 years and older to determine whether they respond
differently than younger subjects.
Glucose-6-phosphate Dehydrogenase (G6PD) Deficiency
Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency
may be more prone to methemoglobinemia and hemolysis (see Warnings
and Precautions).
ACZONE ® Gel 5% and vehicle were evaluated in a randomized,
double-blind, crossover design clinical study of 64 subjects with G6PD
deficiency and acne vulgaris. Subjects were Black (88%), Asian (6%),
Hispanic (2%), or of other racial origin (5%). Blood samples were taken at
Baseline, Week 2, and Week 12 during both vehicle and ACZONE ® Gel 5%
treatment periods. Some of these subjects developed laboratory changes
suggestive of hemolysis, but there was no evidence of clinically significant
hemolytic anemia in this study (see Warnings and Precautions).
Rx ONLY
© 2016 Allergan. All rights reserved.
Irvine, CA 92612 U.S.A.
All trademarks are the property of their respective owners.
APC24AJ16 160549
Based on package insert 72780US10
WELCOME TO THE 2017 AAD ANNUAL MEETING
10
GREAT WAYS
LEARN THE
LATEST SCIENCE
Late-breaking research
#1
SATURDAY
LOCATION: SEE BELOW
Are you looking for the most
groundbreaking research in
dermatology? Then look no
further than the popular “Latebreaking research” sessions. There will
be four different forums:
• F056 – Clinical Trials. 9-11 a.m.,
Room W415D
• F072 – Clinical Studies/Pediatric.
1-3 p.m., Room W308A
• F073 – Procedural Dermatology.
1-3 p.m., Room W304C
• F085 – Basic Science/Cutaneous
Oncology/Pathology. 3:30-5:30 p.m.,
Room W304A
Many exhibitors offer in-booth, hands-on
opportunities to try their products.
10
Experience AAD in Orlando
to experience everything the 2017
AAD Annual Meeting has to offer.
These forums will highlight the latest in
clinical, surgical, and pediatric dermatology,
as well as dermatopathology, therapeutics,
and basic research. Researchers were invited
to submit abstracts describing their most
recent results. The authors of the topscoring studies will discuss their findings
in a brief oral presentation. Afterwards,
attendees will be able to accurately describe
groundbreaking scientific developments
in dermatologic research and apply
information from recent investigations into
their own clinical practices.
BE INSPIRED
AT THE PLENARY
SUNDAY, 8-11:30 A.M.
LOCATION: CHAPIN
THEATER
#2
A highlight of
every Annual
Meeting is
the Plenary
session, which
features lectures from
various leaders in the specialty and the
presentation of cutting-edge research.
The session opens with the AAD and
AADA Annual Business Meeting, and
also features lectures by AAD President
Abel Torres, MD, JD, and President-Elect
Henry W. Lim, MD.
Other lectures presented during the Plenary are:
The Clarence S. Livingood, MD,
Award and Lectureship
“Telemedicine and the Future of
Medicine,” by Carrie L. Kovarik, MD
The Eugene J. Van Scott Award for
Innovative Therapy of the Skin and the
Phillip Frost Leadership Lecture
“Propranolol in Infantile Hemangiomas:
A Successful Drug Repurposing,” by
Christine Léauté-Labrèze, MD
The Lila and Murray Gruber Memorial
Cancer Research Award and Lectureship
“How Moles Become Cancer,” by Boris C.
Bastian, MD, PhD
The Marion B. Sulzberger, MD, Memorial
Award and Lectureship
“Getting to the Heart (and Other
Comorbidities) of Psoriasis,” by Joel M.
Gelfand, MD, MSCE
Guest Speaker
“The West African Ebola Epidemic and
the Global Health Security Agenda,” by
RADM Jordan W. Tappero, MD, MPH
See page 28 for complete Plenary information.
EXPLORE THE
EXHIBIT HALL
LOCATION: WEST HALLS A2-B3
Visit the Exhibit Hall to find
more than 400 exhibitors
showcasing the latest
products and services
for the dermatology
specialty.
#3
Guest access to the Exhibit
Hall is limited to Sunday.
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
WELCOME TO THE 2017 AAD ANNUAL MEETING
WELCOME
EDUCATION
For a full list of educational sessions, visit aad.org/AM17 and click on the Education icon, or access through the AAD Meeting Mobile App.
Live Demonstration sessions
Friday................................... 10 a.m.-5 p.m.
Unopposed hours............. 12-1 p.m.
Saturday............................... 10 a.m.-5 p.m.
Unopposed hours............. 12-1 p.m.
Sunday................................. 10 a.m.-3 p.m.
Unopposed hours............. 12-1 p.m.
FRIDAY AND SATURDAY
LOCATION: ROOM W415B
EXPAND YOUR
EDUCATION
MONDAY
LOCATION: VARIOUS ROOMS
Formerly known as “Board Prep for
Residents,” this popular session will provide
attendees with hands-on experience by
taking a simulated, shortened version of the
ABD certification exam.
Botulinum Toxin: Video
Instruction and Live Panel
Discussion (C003)
FRIDAY, 9 A.M.-12 P.M.
LOCATION: ROOM W314B
Master injectors will share video
techniques and pearls in an interactive
session, while presenters challenge them
with novel approaches that can be put to
use immediately in any practice.
Rewards and Awards: How to
Make QI Pay Off (S029)
SATURDAY, 1-4 P.M.
LOCATION: ROOM W206C
This session will be geared toward
residents, with the last hour being a
competition among attendees.
Improve psoriasis and psoriatic
arthritis treatment (W002)
FRIDAY, 1-3 P.M.
LOCATION: ROOM W314B
“Practical Approaches to Assessing
Psoriasis and Psoriatic Arthritis Patients
in Clinic” will explain how to determine
disease severity and use quality-of-life tools
to treat patients. The session will consist
of five didactic presentations, interactive
patient assessment demonstrations, and
virtual patient assessment experiences.
MOC self-assessment
The American Board of Dermatology has
expanded the number of sessions eligible
for MOC self-assessment credits, including
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
aad.org 11
NOTES
The Academy has expanded its popular
procedural workshops, including “Handson: Fire and Ice! Electrosurgery and
Cryosurgery” (W014) and “Hands-on:
Practical Anatomy for Dermal Fillers”
(W010/W018). Other hands-on session
topics include lasers, scar revision, nail
surgery, suture techniques, wound closures,
and varicose and telangiectatic veins.
FRIDAY, 9 A.M.-4 P.M.
LOCATION: ROOM W414A (morning
session); ROOM W311A (afternoon sessions)
Panel members will present common but
difficult cases that represent medical,
surgical, and pediatric dermatology, and
an audience response system will help
benchmark how other members of the
audience would manage the patient.
CITY GUIDE
Hands-on workshops
Conquer the Boards:
An Experiential Review
(C006)
SUNDAY, 1-4 P.M.
LOCATION: ROOM W304G
MAPS
#4
The 2017 AAD Annual
Meeting offers learning
opportunities in a variety
of formats, such as handson experiences, simulated
patient encounters, and trending
topics. For a full list of educational
opportunities, go to aad.org/meetings/
AM17 and click on the Education icon, or
access the list through the AAD Meeting
Mobile app.
Three Live Demonstration sessions will
include “Live Demonstration: The State
of the Art of Aesthetic Dermatology”
(C009), “Live Demonstration: Soft Tissue
Augmentation and Neuromodulators
— Simultaneous Cadaver Prosection
and Live Patient Injections” (C012), and
“Live Demonstration: Head and Neck
Anatomy” (C019).
Managing Tough Real Life
Dermatology Cases (S039)
EXHIBIT HALL
Exhibit Hall hours
WELCOME TO THE 2017 AAD ANNUAL MEETING
all hands-on and audience response system
sessions, in addition to the traditional
question-based sessions.
Patient Encounter workshops
FRIDAY, SATURDAY, AND SUNDAY
LOCATION: ROOM W205A
Sharpen your patient communication
skills with these unique workshops offered
in a one-on-one setting. Interact with an
actor-patient to practice real topics such as
medication management, difficult patients,
total body skin exam, and breaking bad
news.
Gross and Microscopic
Symposium (S009)
Conquer the Boards: An Experimental Review — taking place from 9 a.m. to 4 p.m. Friday, in Room
W414AB — provides a chance to take a simulated shortened version of the ABD certification exam.
FRIDAY AND SATURDAY, 9 A.M.-5 P.M.
LOCATION: ROOM W306A
Access the entire meeting
program at your fingertips
The “Gross and Microscopic” symposium
will feature five speakers discussing a variety
of dermatologic cases with clinical, surgical,
and pathological correlations. The two-day
symposium entails 192 presentations, which
will cover the gamut of clinical dermatology,
predicated on clinical/pathological
correlation, with attention to new and
interesting observations. Presentations will
be grouped into clinical categories allowing
attendees to focus on particular conditions/
entities. Each presentation will be five
minutes, and will be clinically germane and
applicable to patient care. The symposium is
open to all AAD members, non-members,
residents/fellows, and medical students.
The Academy has made it easier than ever to
search the online program. Multiple viewing
options are available under the Education icon
on the Annual Meeting web page at aad.org/
AM17, or on the AAD Meeting Mobile App.
In addition to a searchable, updated program
link where attendees can search sessions by
unique keywords or session number, there is
also a digital flipbook that allows attendees
to flip through pages of the program, zoom
in on interesting content, and view or print a
PDF from the digital link.
DISCOVER GLOBAL
INITIATIVES
Hot Topics (S024)
SATURDAY, 1-4 P.M.
LOCATION: CHAPIN THEATER
#5
Attend the “Hot Topics”
symposium, led by the session
director, Kenneth J. Tomecki,
MD, to hear about new and
emerging therapies for the
treatment of dermatological diseases
and aesthetic challenges in clinical practice.
Presentations are expected to touch on
topics such as contact dermatitis, health
care reform, and facial sculpting and fillers,
as well as new and emerging therapies for
acne and atopic dermatitis. Speakers will
provide information about cutting-edge
treatments that have recently become
available or will likely become part of the
therapeutic armamentarium in the future.
12
Experience AAD in Orlando
International Day
of Dermatology
THURSDAY
LOCATION: VARIOUS ROOMS
The International Day of
Dermatology is an opportunity
for societies from around the globe to
invite speakers to develop and conduct an
educational program that will highlight the
work of their members.
The following organizations will be hosting
independent sessions:
• Academia Española de Dermatología y
Venereología
• The Association of Cutaneous Surgeons
of India
• The Chinese Society of Dermatology
• The Dermatological Society of
Singapore
• The European Society of Lasers and
Energy Based Devices
• The International Dermoscopy Society
• The International Forum for the Study
of Itch
• The International Peeling Society
• The International Society for
Dermatologic Surgery
• The Mexican Academy of Dermatology
• The Polish Dermatological Society
• The Society of Dermatologists,
Venereologists and Leprologists of
Nepal
• The International Psoriasis Council
The International Day of Dermatology
is separate from the Annual Meeting
registration. Visit aad.org/AM17 for
registration information.
NETWORK
The AAD Career
Networking Event
FRIDAY, 5-7 P.M.
LOCATION: REGENCY
BALLROOM S, HYATT
REGENCY ORLANDO
#6
Explore and learn about various practicesetting opportunities at the AAD Career
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
WELCOME TO THE 2017 AAD ANNUAL MEETING
Networking Lounges
in The Connection
FRIDAY-MONDAY, 8 A.M.-5 P.M.
LOCATION: HALL B4
GET INVOLVED
On-site events
#7
#8
Networking with colleagues is one of the greatest
benefits of attending the Annual Meeting.
•
•
•
AAD Resource Center
FRIDAY-MONDAY, 8 A.M.-5 P.M.
LOCATION: HALL B4
•
The AAD Resource Center is your one-stop
shop to learn about AAD resources and new
products, with an expert staff available to
assist you one-on-one. Among the services:
• Enroll and demo AAD’s DataDerm™
• Discover the new Practice Management
Center which features the latest resource
•
•
•
designed to help you navigate the everchanging practice environment
Professional CV/Resume review and
post a CV or job on AAD job board
Come take your #AAD17 selfie with
your friends at the selfie station
Get a professional head shot taken for
free – head shots delivered digitally after
the meeting
Experience Membership – renew or
apply for membership
Demo the latest digital products, apps,
publications, and services
Pre-order Annual Meeting On-Demand
recordings
Save 10 percent on select AAD
products
CITY GUIDE
New Election Voting Timeline
The 2017 AAD Election opens on
March 4 at 12:01 a.m. (ET). You can
conveniently access the Academy Election
site at aad.org/aadelection. All ballots
must be received or electronically posted
by 11:59 p.m. Eastern time, March 18.
The Connection is the central location
for Annual Meeting attendees to come
together, view e-Posters,
use interactive
service stations,
take a break in
the Networking
Lounge, and
visit the AAD
Resource Center.
The Connection is
where you will find:
• e-Poster Viewing Centers: Get an
in-depth view of new and innovative
research as you explore electronic poster
exhibits
• Poster Presentation Theaters: Listen to
e-Poster authors discuss their work while
you discover pearls from their posters
• AAD Board of Directors Meet and
Greet (12-1 p.m., Friday and Saturday)
Get to know the candidates
The Connection, located in Hall B4, is your home for all things AAD. Stop by to find networking
opportunities, interactive service stations, e-Posters, and the AAD Resource Center.
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
aad.org 13
NOTES
Visit aad.org/aadelection to view
the candidates’ background materials,
including optional letters and the ballot
book, and see information about the
proposed bylaws amendment. The
president-elect speeches presented at
the Annual Business Meeting will be
posted to the election site by Monday,
March 6.
MAPS
AAD Election
FRIDAY-MONDAY,
8 A.M.-5 P.M.
LOCATION: HALL B4
EXHIBIT HALL
A number of
the councils,
committees,
task forces,
and affiliate and
reunion groups of
the AAD will meet and
have events during the Annual Meeting.
Go to the Annual Meeting website at
aad.org/AM17, and click on the General
Information icon to download the list of
events, or access them through the AAD
Meeting Mobile app. All such events will
be held at the Hilton Orlando or the Hyatt
Regency Orlando, unless otherwise listed.
The Connection
EDUCATION
Make new connections, catch up with
colleagues, check email, or charge your
phone. You can also access voting,
complete airline check-in, and claim CME
at the e-Center.
CONNECT WITH AAD
WELCOME
Networking Event. Visit with employers
who are looking to hire dermatologists, and
meet with AAD representatives to gain tips
for how to take advantage of AAD’s online
career center at aadcareercompass.org.
WELCOME TO THE 2017 AAD ANNUAL MEETING
• Learn how to incorporate patient
education for both the waiting and exam
room with our new affinity partner,
Outcome Health
• Receive customized financial solutions
for your short-term and long-term
aspirations with our new affinity
partners Bank of America Practice
Solutions and Outcome Health
Use all the features of the
AAD Meeting Mobile App
Navigating the Annual Meeting is easy
with the AAD Meeting Mobile App. With
this easy-to-use app, you’ll gain access to:
• Session schedule: Listing of sessions
by day, type, category, and speaker;
bookmark sessions you like, take notes,
or access select session handouts
• Exhibitors: Search by name and
category, or view the exhibit hall
floor plan
• Speakers: Search by names and
see the sessions in which they’re
speaking
• Maps: Explore floor plans for
session rooms
• AskMe: Discover answers to frequently
asked questions
• Event listings: Peruse listings for council,
committee, and task force meetings;
affiliate and reunion groups; Industry
Expert Sessions; and Industry NonCME programs
• e-Posters: Search e-Posters by author,
title, category, keyword, or poster number
• City guide: Find information on all
things related to Orlando
• Audience Response Sessions: Access and
participate in Audience Response Sessions
To download, go to your phone’s app store,
or visit aad.org/mobile.
JOIN THE DIGITAL
DISCUSSION
The Academy has merged its Twitter
accounts and renamed it @AADmember.
If you were already following the Meeting
News Twitter feed, you will continue to see
updates about the Meeting under the
new @AADmember name. If
you weren’t following the
Meeting News Twitter
before, start following @
AADmember today.
#9
TAKE AAD HOME
WITH YOU
Annual Meeting
session recordings
14
Experience AAD in Orlando
THE ORANGE COUNTY
CONVENTION CENTER OFFERS
SEVERAL FOOD COURTS.
• Visit the AAD Food Court, located
at the back of Exhibit Hall A-B on
the second floor.
• Food courts are located on the
lower levels of the West Building.
• A variety of portable hospitality
carts are located on all levels,
serving beverages and snacks.
The food courts offer barbecue
foods, deli sandwiches, burgers,
and pizzas, as well as international
menus of Greek, Chinese, French,
Italian, and Japanese food.
Options include freshly prepared
menu items with healthy options.
Be sure to also like the
new Facebook page designed
specifically for AAD members (@
AADmember), which will be updating
followers with news and information about
the Annual Meeting, including posts about
new and popular sessions, special events,
tourist information, and, of course, shared
photos of members and attendees enjoying
the meeting.
To share your photos with the AAD, use the
official meeting hashtag #AAD17 in all your
posts and tweets to engage in conversations
and activities throughout the meeting.
•Facebook: facebook.com/AADmember
•Twitter: twitter.com/AADmember
The AAD Meeting Mobile App is your source
for the most up-to-date meeting information.
Download the app at aad.org/mobile.
FOOD OPTIONS IN
CONVENTION CENTER
With Annual Meeting
On-Demand Recordings,
you can experience the most
popular sessions from the 2017
AAD Annual Meeting. Revisit a
session or catch one you missed.
Learn about AAD resources and new products
in the Resource Center.
This thorough educational offering brings
you a variety of educational sessions with
slides synchronized to audio. Visit
#10
aad.org/meetings/annual-meeting/
on-demand-recordings for a
complete listing of session
recordings.
To purchase on site, visit the AAD
Resource Center in Hall B4. The
price is $149 when you pre-order by
March 8.
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
83
%
OF SK PATIENTS
ARE INTERESTED
IN TREATMENT
and willing to pay
out-of-pocket1
MORE THAN 83 MILLION
2
AMERICANS HAVE SK.
Many SK patients feel embarrassed about their skin, worry about
looking older, and struggle to cover, disguise or deal with the
condition.1 SK matters to patients and impacts their daily lives.1
The majority of patients with SK are interested in a treatment option
that is unlikely to scar and does not involve cutting, burning or freezing.1
Learn more at booth #3526 and SKMatters.com
Data on File. Aclaris Therapeutics SK In-office Observational Study, 406 dermatology patients, 2016.
Bickers DR, et al. The burden of skin diseases: 2004. J Am Acad Dermatol 2006; 55:490-500.
1
2
© 2017 Aclaris Therapeutics Inc. All Rights Reserved.
IT ALL HAPPENS
GENERAL AND MEDICAL DERMATOLOGIST AT
CARILION CLINIC AND THE VIRGINIA TECH
CARILION SCHOOL OF MEDICINE
ROANOKE, VIRGINIA
The Division of Dermatology and Mohs Surgery is seeking
a ABMS/AOA- BE/BC Dermatologist. The current practice
offers medical/general dermatology, Mohs surgery, and
dermatopathology in an academic setting that includes an
ACGME accredited dermatology residency program. A pulsed
dye laser, blue light unit, narrow band ultraviolet light booth,
and hand and foot unit are available. The ideal candidate
should have a strong interest in medical/general dermatology
and teaching. Opportunities for clinical research, lasers and
cosmetics are available if desired. Carilion has a large primary
care referral base of 200+ physicians throughout southwest
Virginia.
For more information or to submit your CV for
consideration please contact Andrea Henson,
physician recruiter, at [email protected]
or 540-224-5241.
7 hospitals | 680+ physicians | 70+ specialties | 220 practice sites | 23 GME programs
G147525 AM Dermatology Recruit ad 7x5.indd 1
Equal Opportunity Employer - Minorities • Females • Protected Veterans • Individuals with Disabilities
12/16/16 11:15 AM
BOTOX® Cosmetic (onabotulinumtoxinA) IMPORTANT SAFETY
INFORMATION (continued)
CONTRAINDICATIONS
BOTOX® Cosmetic is contraindicated in the presence of infection at the
proposed injection site(s) and in individuals with known hypersensitivity
to any botulinum toxin preparation or to any of the components in
the formulation.
WARNINGS AND PRECAUTIONS
Lack of Interchangeability between Botulinum Toxin Products
The potency Units of BOTOX® Cosmetic are specific to
the preparation and assay method utilized. They are not
interchangeable with other preparations of botulinum toxin
products and, therefore, units of biological activity of
BOTOX® Cosmetic cannot be compared to nor converted into
units of any other botulinum toxin products assessed with any
other specific assay method.
Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
No definitive serious adverse event reports of distant spread of toxin effect
associated with dermatologic use of BOTOX® Cosmetic at the labeled
dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines),
44 Units (for simultaneous treatment of lateral canthal lines and glabellar
lines) have been reported.
Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia,
and aspiration pneumonia, with some adverse reactions associated with
fatal outcomes, have been reported in patients who received BOTOX®
injections for unapproved uses. In these cases, the adverse reactions
were not necessarily related to distant spread of toxin, but may have
resulted from the administration of BOTOX® to the site of injection and/
or adjacent structures. In several of the cases, patients had pre-existing
dysphagia or other significant disabilities. There is insufficient information
to identify factors associated with an increased risk for adverse reactions
associated with the unapproved uses of BOTOX®. The safety and
effectiveness of BOTOX® for unapproved uses have not been established.
Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported.
These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue
edema, and dyspnea. If such reactions occur, further injection of
BOTOX® Cosmetic should be discontinued and appropriate medical
therapy immediately instituted. One fatal case of anaphylaxis has been
reported in which lidocaine was used as the diluent and, consequently,
the causal agent cannot be reliably determined.
Cardiovascular System
There have been reports following administration of BOTOX® of adverse
events involving the cardiovascular system, including arrhythmia and
myocardial infarction, some with fatal outcomes. Some of these patients
had risk factors including pre-existing cardiovascular disease. Use caution
when administering to patients with pre-existing cardiovascular disease.
Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic
lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia
gravis or Lambert-Eaton syndrome) should be monitored when given
botulinum toxin. Patients with neuromuscular disorders may be at
increased risk of clinically significant effects including generalized muscle
weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia,
and respiratory compromise from onabotulinumtoxinA (see Warnings
and Precautions).
Dysphagia and Breathing Difficulties
Treatment with BOTOX® and other botulinum toxin products can
result in swallowing or breathing difficulties. Patients with pre-existing
swallowing or breathing difficulties may be more susceptible to these
complications. In most cases, this is a consequence of weakening
of muscles in the area of injection that are involved in breathing or
oropharyngeal muscles that control swallowing or breathing (see
Boxed Warning).
Pre-existing Conditions at the Injection Site
Caution should be used when BOTOX® Cosmetic treatment is used in
the presence of inflammation at the proposed injection site(s) or when
excessive weakness or atrophy is present in the target muscle(s).
Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on
effective donor screening and product manufacturing processes, it carries
an extremely remote risk for transmission of viral diseases. A theoretical
risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered
extremely remote. No cases of transmission of viral diseases or CJD have
ever been identified for albumin.
ADVERSE REACTIONS
The most frequently reported adverse event following injection of
BOTOX® Cosmetic for glabellar lines was eyelid ptosis (3%).
The most frequently reported adverse event following injection
of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).
DRUG INTERACTIONS
Co-administration of BOTOX® Cosmetic and aminoglycosides or
other agents interfering with neuromuscular transmission (eg, curarelike compounds) should only be performed with caution as the
effect of the toxin may be potentiated. Use of anticholinergic drugs
after administration of BOTOX® Cosmetic may potentiate systemic
anticholinergic effects.
The effect of administering different botulinum neurotoxin products
at the same time or within several months of each other is unknown.
Excessive neuromuscular weakness may be exacerbated by
administration of another botulinum toxin prior to the resolution of
the effects of a previously administered
botulinum toxin.
Excessive weakness may also be exaggerated by administration of a
muscle relaxant before or after administration of BOTOX® Cosmetic.
USE IN SPECIFIC POPULATIONS
BOTOX® Cosmetic is not recommended for use in
children or pregnant women. It is not known whether
BOTOX® Cosmetic is excreted in human milk. Caution
should be exercised when BOTOX® Cosmetic is
administered to a nursing woman.
Please see brief summary of full Prescribing
Information on the following pages.
Actual patient treated for moderate
to severe crow’s feet and glabellar lines.
Results may vary.
© 2017 Allergan. All rights reserved.
BotoxCosmetic.com 1-800-BOTOXMD BCT78079_v2 11/16 153566
We’re already on a first-name basis
You can feel confident giving her the brand she asks about by name
Indications
Glabellar Lines
BOTOX® Cosmetic (onabotulinumtoxinA) for injection is indicated for the
temporary improvement in the appearance of moderate to severe glabellar lines
associated with corrugator and/or procerus muscle activity in adult patients.
Lateral Canthal Lines
BOTOX® Cosmetic is indicated for the temporary improvement in the
appearance of moderate to severe lateral canthal lines associated with
orbicularis oculi activity in adult patients.
IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce
symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia,
dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and
breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for
spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying
condition that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of
spread of effect have been reported at doses comparable to those used to treat cervical dystonia and upper limb spasticity and at lower doses.
Please see additional Important Safety Information about BOTOX® Cosmetic on opposite page.
WELCOME TO THE 2017 AAD ANNUAL MEETING
DAILY highlights
THURSDAY
FRIDAY
TIME
EVENT
8 a.m.-6 p.m.
International Day of Dermatology.
Visit aad.org/meetings for more information.
12-6 p.m
AAD onsite registration open
West B lobby
Industry Non-CME Program.
Clinical Insights on Taltz
Hyatt Regency
Orlando,
Regency
Ballroom U
Industry Non-CME Program.
Introducing a new nonsteroidal
topical prescription treatment
option for mild-to-moderate atopic
dermatitis
Hyatt Regency
Orlando,
Regency
Ballroom T
7 p.m.
(Registration
is at 6:30 p.m.)
LOCATION
TIME
EVENT
LOCATION
7 a.m.-5:30 p.m.
AAD registration open
West Lobby B
8 a.m.-5 p.m.
AAD Resource Center open
Hall B4
9 a.m.-12 p.m.
S004 – Therapeutic Hotline
Chapin Theater
9 a.m.-4 p.m.
C006 – Conquer the Boards:
An Experiential Review
Room W414AB
11-11:15 a.m.
Industry Expert Session. Moving
Beyond Topicals: Perspectives on
Systemic Treatment for Psoriasis
Exhibit Hall
12-1 p.m.
UNOPPOSED EXHIBIT TIME
12-1 p.m.
AAD Board of Directors Meet and
Greet
The Connection,
Hall B4
12:15-1 p.m.
Industry Expert Session. You’ve Got
Options: The Changing Paradigm of
Plaque Psoriasis Treatment
Exhibit Hall
1:30-2:15 p.m.
Industry Expert Session. Allergan
Medical Dermatology
Exhibit Hall
3:30-5:30 p.m.
Young Physician Pearls and Pitfalls.
A Survival Guide for the First 10
Years
Room W308AB
Resident Reception
Hyatt Regency
Ballroom
Young Physician and New Member
Reception
Hyatt Regency
Ballroom
International Member Reception
Hyatt Regency
Ballroom
AAD Career Networking Event
Hyatt Regency
Ballroom S
Industry Non-CME Program.
JUVÉDERM VOLUMA® XC and
JUVÉDERM VOLBELLA® XC Tailored
to Meet Your Patients’ Needs
Hilton Orlando,
Orlando
Ballroom III
Industry Non-CME Program.
Breakthrough Innovations from
SkinMedica for patients with
Hyperpigmentation – Lytera 2.0
Hilton Orlando,
Lake George
Industry Non-CME Program.
Horizons in Pediatric Moderate to
Severe Plaque Psoriasis
Hilton Orlando,
Orlando
Ballroom II
5-6:30 p.m.
5-7 p.m.
7 p.m.
(Registration
is at 6:30 p.m.)
7:30 p.m.
(Registration
is at 7 p.m.)
18
Experience AAD in Orlando
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
WELCOME TO THE 2017 AAD ANNUAL MEETING
EVENT
12:01 a.m. (ET)
AAD election opens
LOCATION
7 a.m.-5:30 p.m.
AAD registration open
West Lobby B
8 a.m.-5 p.m.
AAD Resource Center open
Hall B4
9-11 a.m.
F056 – Late-breaking Research:
Clinical Trials
Room W415D
11-11:15 a.m.
Industry Expert Session. Cosentyx
Exhibit Hall
12-1 p.m.
UNOPPOSED EXHIBIT TIME
12-1 p.m.
AAD Board of Directors Meet and
Greet
12:15-1 p.m.
Industry Expert Session. In Atopic
Dermatitis, Looks Can be Deceiving
West Lobby B
8 a.m.-5 p.m.
AAD Resource Center open
Hall B4
8-11:30 a.m.
PLENARY SESSION
CHAPIN THEATER
11-11:45 a.m.
Industry Expert Session.
Introducing a new nonsteroidal
topical prescription treatment
option for mild-to-moderate
atopic dermatitis
Exhibit Hall
12-1 p.m.
UNOPPOSED EXHIBIT TIME
12:15-1 p.m.
Industry Expert Session. Biosimilars
in Psoriasis: Insights Into the
Evidence evaluation of a biosimilar
Exhibit Hall
1-4 p.m.
S032 – Resident Jeopardy
W304CD
1-4 p.m.
S038 – Psoriasis
Chapin Theater
1:30-2:15 p.m.
Industry Expert Session. IL-23
BIOLOGY AND ITS ROLE IN THE
PATHOGENESIS OF PSORIASIS
Exhibit Hall
3:30-5:30 p.m.
F116 – Boards and Beyond
Room W307AB
Industry Non-CME Program.
The Latest on Key Nutrients,
Dietary Supplementation, and
Healthy Skin: A Virtual Reality
Learning Experience
Hilton Orlando,
Florida Ballroom
5/6/7
Industry Non-CME Program.
The COSENTYX® (secukinumab)
Experience: Patient and HCP
Perspectives
Hilton Orlando,
Florida Ballroom
1/2/3
Industry Non-CME Program.
New Horizons: Finally,
Approaches to Treating Moderate
to Severe Atopic Dermatitis
Hilton Orlando,
Florida Ballroom 4
7 p.m. (Registration
is at 6:30 p.m.)
The Connection,
Hall B4
F072 – Late-breaking Research:
Clinical Studies/Pediatric
Room W308AB
F073 – Late-breaking Research:
Procedural Dermatology
W304CD
S024 – Hot Topics
Chapin Theater
Industry Expert Session. Cosentyx
Exhibit Hall
2:45-3:30 p.m.
Industry Expert Session. Spotlight
on CIU: Vicki Lawrence’s Story
Exhibit Hall
3:30-5:30 p.m.
F085 – Late-breaking Research:
Basic Science/Cutaneous
Oncology/Pathology
Room W304AB
7 p.m. (Registration
is at 7 p.m.)
Industry Non-CME Program.
Atopic Dermatitis Assessment
Tools … Not So EASI
Hilton Orlando,
Orlando
Ballroom II
7:30 p.m.
(Registration
is at 6:30 p.m.)
Industry Non-CME Program.
Androgenic Alopecia: New
Approaches on the Horizon
Hilton Orlando,
Lake Nona
MONDAY
TIME
EVENT
LOCATION
7 a.m.-5:30 p.m.
AAD registration open
West Lobby B
8 a.m.-5 p.m.
AAD Resource Center open
Hall B4
9 a.m.-12 p.m.
S049 – Boards Blitz
Room W208ABC
CITY GUIDE
1-4 p.m.
1:30-2:15 p.m.
MAPS
1-3 p.m.
LOCATION
AAD registration open
EXHIBIT HALL
TIME
EVENT
7 a.m.-5:30 p.m.
EDUCATION
SATURDAY
TIME
WELCOME
SUNDAY
TUESDAY
TIME
EVENT
LOCATION
7:30 a.m.-12:30 p.m.
AAD registration open
West Lobby B
8-10 a.m.
S068 – Therapeutics and
Diagnostic Pearls
Room W415A
10:30 a.m.12:30 p.m.
S069 – What’s New in Dermatology
Room W415A
NOTES
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
aad.org 19
WELCOME TO THE 2017 AAD ANNUAL MEETING
Honors and awards
Below is a list of former AAD officers and current and past AAD award winners.
PAST PRESIDENTS OF AAD
1938
1939
1940
1941
1942-46
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990 1991
1992
1993
Howard Fox, MD*
Paul A. O’Leary, MD*
Harry R. Foerster, MD*
Richard S. Weiss, MD*
George M. MacKee, MD*
Edward A. Oliver, MD*
Clyde L. Cummer, MD*
Francis E. Senear, MD*
Earl D. Osborne, MD*
Donald M. Pillsbury, MD*
C. Guy Lane, MD*
Michael H. Ebert, MD*
Fred D. Weidman, MD*
Arthur C. Curtis, MD*
George M. Lewis, MD*
Nelson P. Anderson, MD*
James R. Webster, MD*
Anthony C. Cipollaro, MD*
Francis W. Lynch, MD*
Wiley M. Sams, Sr., MD*
J. Walter Wilson, MD*
Robert R. Kierland, MD*
Clinton W. Lane, MD*
Carl T. Nelson, MD*
Herman Beerman, MD*
Clarence S. Livingood, MD*
Stanley E. Huff, MD*
Walter C. Lobitz, Jr., MD*
Edward C. Cawley, MD*
J. Lamar Callaway, MD*
Walter B. Shelley, MD*
John R. Haserick, MD*
Frederick A.J. Kingery, MD*
Rudolf L. Baer, MD*
Harry L. Arnold, Jr., MD*
John M. Shaw, MD*
Rees B. Rees, MD*
Robert W. Goltz, MD*
Alfred W. Kopf, MD
Harold O. Perry, MD*
John H. Epstein, MD
John S. Strauss, MD*
Richard L. Dobson, MD
Clayton E. Wheeler, Jr.,
MD*
Samuel L. Moschella, MD
Richard B. Odom, MD
G. Thomas Jansen, MD*
Edgar B. Smith, MD*
J. Graham Smith, Jr., MD*
Stephen B. Webster, MD
Wilma F. Bergfeld, MD
Mark V. Dahl, MD
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
Peyton E. Weary, MD*
Rex A. Amonette, MD
W. Mitchell Sams, Jr., MD
Roger I. Ceilley, MD
Lynn A. Drake, MD
Darrell S. Rigel, MD
Richard K. Scher, MD
Ronald G. Wheeland, MD
Fred F. Castrow II, MD
Raymond L. Cornelison, Jr., MD
Boni E. Elewski, MD
Clay J. Cockerell, MD
Stephen P. Stone, MD
Diane R. Baker, MD
C. William Hanke, MD, MPH
David M. Pariser, MD
William D. James, MD
Ronald L. Moy, MD
Daniel M. Siegel, MD, MS
Dirk M. Elston, MD
Brett M. Coldiron, MD
Mark Lebwohl, MD
Abel Torres, MD, JD
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
PAST VICE PRESIDENTS
OF AAD
1938
1939
1940 1941
1942-46
1947 1948 1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960 1961
1962 1963
1964
1965
1966
Paul A. O’Leary, MD*
Harther L. Kems, MD*
Clark W. Finnerud, MD*
J.G. Downing, MD*
Everett C. Fox, MD*
William H. Guy, MD*
Frances E. Senear, MD*
Frank C. Combes, MD*
Francis W. Lynch, MD*
James L. Pipkin, MD*
Michael H. Ebert, MD*
Maurice J. Costello, MD*
John F. Madden, MD*
Carroll S. Wright, MD*
Samuel W. Becker, MD*
Arthur G. Schoch, MD*
Everett R. Seale, MD*
Norman M. Wrong, MD*
C. Ferd Lehmann, MD*
Thomas Butterworth, MD*
Lamuel P. Ereauxm, MD*
Louis H. Winer, MD*
Frederick J. Szymanski, MD*
Harry L. Arnold, Jr., MD*
Rees B. Rees, MD*
1967 1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011 2012
2013
2014
2015
2016
Anthony N. Domonkos, MD*
Otis F. Jillson, MD*
Victor H. Witten, MD*
Hermann Pinkus, MD*
Harold N. Cole, Jr., MD*
John L. Fromer, MD*
Margaret A. Storkan, MD*
Adolph Rostenberg, Jr., MD*
Herbert Mescon, MD*
Harold O. Perry, MD*
Morris Waisman, MD*
Donald J. Birmingham, MD*
Richard L. Dobson, MD
Gordon C. Sauer, MD*
James H. Graham, MD*
Samuel L. Moschella, MD
Victor D. Newcomer, MD*
Denny L. Tuffanelli, MD*
Harry L. Wechsler, MD*
Milton Orkin, MD*
Edward A. Krull, MD*
Marvin A. Chernosky, MD*
Frederick D. Malkinson, MD
Diane R. Baker, MD
Paul M. Lazar, MD*
Peter J. Lynch, MD
W. Mitchell Sams, Jr., MD
Lawrence A. Norton, MD*
Alan R. Shalita, MD*
Paul S. Russell, MD
Antoinette F. Hood, MD
Richard K. Scher, MD
Roy S. Rogers III, MD
Marianne N. O’Donoghue, MD
Boni E. Elewski, MD
Neil A. Swanson, MD
Joseph L. Jorizzo, MD
Jeffrey P. Callen, MD
Bruce H. Thiers, MD
William P. Coleman III, MD
Henry W. Lim, MD
James S. Taylor, MD
Evan R. Farmer, MD
Andrew P. Lazar, MD, MPH
Suzanne M. Connolly, MD
Zoe D. Draelos, MD
Lisa A. Garner, MD
Elise A. Olsen, MD
Timothy G. Berger, MD
Kenneth J. Tomecki, MD
PAST SECRETARYTREASURERS OF AAD
1938-41
Clyde L. Cummer, MD, Treasurer*
1938-41 Earl D. Osborne, MD, Secretary*
1946-49 Earl D. Osborne, MD*
1950-53 John E. Rauschkolb, MD*
1954-57 James R. Webster, MD*
1958-62 Robert R. Kierland, MD*
1963-67 Stanley E. Huff, MD*
1968
Robert Pommerening, MD*
1969-73 Frederick A.J. Kingery, MD*
1974-76 John M. Shaw, MD*
1977-79 Walter G. Larsen, MD
1980-82 Franklin Pass, MD
1983-85 G. Thomas Jansen, MD*
1986-88 Stephen B. Webster, MD
1989-91 Paul S. Russell, MD
1992-94 Fred F. Castrow II, MD
1995-97 Darrell S. Rigel, MD
1998-2000 June K. Robinson, MD
2001-03 Clay J. Cockerell, MD
2004-06 David M. Pariser, MD
2007-09 Mary E. Maloney, MD
2010-11 Robert D. Greenberg, MD
2012-15 Suzanne M. Olbricht, MD
THE GOLD MEDAL
1962
1963
1966
1967
1972
1975
1978
1984
1986 1987
1989
1990
1991
1992
1993
1995
1996
1997
1998
1999
2000
2001
Henry E. Michelson, MD*
Stephen Rothman, MD*
Donald M. Pillsbury, MD*
Marion B. Sulzberger, MD*
J. Lamar Callaway, MD*
Clarence S. Livingood, MD*
Rudolf L. Baer, MD*
Walter C. Lobitz, Jr., MD*
Naomi M. Kanof, MD*
Rees B. Rees, MD*
Harvey Blank, MD*
Peyton E. Weary, MD*
Robert W. Goltz, MD*
Walter B. Shelley, MD*
Clayton E. Wheeler, Jr., MD*
John S. Strauss, MD*
Edward A. Krull, MD*
G. Thomas Jansen, MD*
Harold O. Perry, MD*
E. William Rosenberg, MD
Alfred W. Kopf, MD
John A. Kenney, Jr., MD*
* Indicates deceased members
20
Experience AAD in Orlando
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
WELCOME TO THE 2017 AAD ANNUAL MEETING
HONORARY MEMBERS
2007 2014
2015
2016
2017
Charles N. Ellis, MD
Norman Goldstein, MD
Alice B. Gottlieb, MD, PhD
Pearl E. Grimes, MD
Maria K. Hordinsky, MD
Douglas R. Lowy, MD
Daniel M. Siegel, MD, MS
John W. Weiss, MD
Jean L. Bolognia, MD
Francisco M. Camacho-
Martinez, MD, PhD
Brett M. Coldiron, MD
Luis A. Diaz, MD
Hugh T. Greenway, Jr.,
MD
Rebat M. Halder, MD
Mary E. Maloney, MD
Stephen H. Mandy, MD
Jorge Ocampo-Candiani, MD
Jorge L. Sanchez, MD
Stephen P. Stone, MD
MASTERS IN
DERMATOLOGY
1984
1985
1985
1985
1986
1987 1987
1987
1988
1988
1989
1989
1990
1990
1991
1991
1992
1992
1993
1993
1994 1994
1994
1995
1995
1996
1996
1997
1997
1998
1998
1999
1999
2003
Rudolf L. Baer, MD*
Harold O. Perry, MD*
Clarence S. Livingood, MD*
Harvey Blank, MD*
Rees B. Rees, MD*
Walter B. Shelley, MD*
J. Lamar Callaway, MD*
Harry L. Arnold, Jr., MD*
Herman Beerman, MD*
Walter C. Lobitz, Jr., MD*
Alexander A. Fisher, MD*
Richard L. Sutton, Jr., MD*
Thomas B. Fitzpatrick, MD, PhD*
Robert W. Goltz, MD*
John H. Epstein, MD
G. Thomas Jansen, MD*
Richard L. Dobson, MD
Samuel L. Moschella, MD
Clayton E. Wheeler, Jr., MD*
Irwin M. Braverman, MD
Albert M. Kligman, MD, PhD*
Lowell A. Goldsmith, MD
Alfred W. Kopf, MD
Marie-Louise Johnson, MD, PhD
John A. Kenney, Jr., MD*
Eugene Farber, MD*
J.B. Howell, MD*
Victor D. Newcomer, MD*
Eugene J. Van Scott, MD
John S. Strauss, MD*
Aaron B. Lerner, MD
Harry J. Hurley, MD*
Peyton E. Weary, MD*
J. Graham Smith, Jr., MD*
* Indicates deceased members
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
aad.org 21
NOTES
2008 2009
2013
Darrell S. Rigel, MD
E. Dorinda Shelley, MD
Ronald G. Wheeland, MD
Gerd Plewig, MD
Jean D.A. Carruthers, MD
Martin M. Black, MD
Paul R. Gross, MD
Robert Jackson, MD
Stephen I. Katz, MD, PhD
Elizabeth I. McBurney, MD
Charles J. McDonald, MD
Vera H. Price, MD
Roger I. Ceilley, MD
C. William Hanke, MD, MPH
Lenore Setsuko Kakita, MD
Bruce A. Deitchman, MD*
Thomas Ruzicka, MD
Darryl M. Bronson, MD, MPH*
Stuart M. Brown, MD
Robert J. G. Chalmers, MBBS
Leonard H. Goldberg, MD
Arthur C. Huntley, MD
David L. McCaffree, MD
John C. Maize, Sr., MD
Amanda M. M. Oakley, MBChB
June K. Robinson, MD
Arnold L. Schroeter, MD
James S. Taylor, MD
James A. Zalla, MD
Jeffrey D. Bernhard, MD
Jeffrey P. Callen, MD
William A. Caro, MD
Hong-Duo Chen, MD
Vincent A. DeLeo, MD
James O. Ertle, MD
Antoinette F. Hood, MD
Charles W. Lewis, MD
O. Fred Miller III, MD
David M. Pariser, MD
Stuart J. Salasche, MD
John R. Stanley, MD
Bruce H. Thiers, MD
Howard P. Baden, MD
Louis L. Barich, MD
Paul R. Bergstresser, MD
Michael E. Bigby, MD
Boni E. Elewski, MD
Lawrence M. Field, MD
Z. Charles Fixler, MD
Smith H. Gibson, MD
Charles L. Heaton, MD
Carl A. Johnson, MD
Howard K. Koh, MD
Anne W. Lucky, MD
James J. Nordlund, MD
Henry H. Roenigk, Jr., MD
Michael D. Tharp, MD
Robert E. Tigelaar, MD
James Q. Del Rosso, DO
CITY GUIDE
1979
1980
1981
1982
1983 1984 1987 2001
2002 2003 2004 2005 2006 2010
2011 2012 MAPS
1972
1974 1975
1978
Andrew Biddle, MD*
William T. Corlett, MD*
William A. Pusey, MD*
Charles J. White, MD*
Fred Wise, MD*
Clyde L. Cummer, MD*
Henry E. Michelson, MD*
Donald M. Pillsbury, MD*
Marion B. Sulzberger, MD*
Charles C. Dennie, MD*
Harry R. Foerster, MD*
Hamilton Montgomery, MD*
Herman Beerman, MD*
Clark W. Finnerud, MD*
Samuel Ayres, Jr., MD*
J. Lamar Callaway, MD*
Everett C. Fox, MD*
Clinton W. Lane, MD*
Wiley M. Sams, MD*
Richard L. Sutton, Jr., MD*
J. Walter Wilson, MD*
Robert R. Kierland, MD*
Francis W. Lynch, MD*
J. Lewis Pipkin, MD*
Samuel J. Zakon, MD*
Clarence S. Livingood, MD*
Adolph Rostenberg, Jr., MD*
Harry L. Arnold, Jr., MD*
Stanley E. Huff, MD*
Frederick A.J. Kingery, MD*
John M. Shaw, MD*
Rudolf L. Baer, MD*
Walter C. Lobitz, Jr., MD*
Hermann Pinkus, MD*
Naomi C. Kanof, MD*
Rees B. Rees, MD*
William Montagna, PhD*
Harold O. Perry, MD*
Walter B. Shelley, MD*
Edward P. Cawley, MD*
Robert W. Goltz, MD*
Clayton E. Wheeler, Jr., MD*
1992 1993 1997 1999 2000 John A. Kenney, Jr., MD*
Aaron B. Lerner, MD*
Harvey Blank, MD*
Thomas B. Fitzpatrick, MD, PhD*
Peyton E. Weary, MD*
William M. Narva, MD
Perry Robins, MD
Eugene J. Van Scott, MD
J.B. Howell, MD*
G. Thomas Jansen, MD*
Edward A. Krull, MD*
J. Graham Smith, Jr., MD*
John S. Strauss, MD*
E. William Rosenberg, MD
Philip C. Anderson, MD*
Richard L. Dobson, MD
James Hebert Graham, MD*
Alfred W. Kopf, MD
Victor D. Newcomer, MD*
Herschel S. Zackheim, MD*
Bradford W. Claxton, CAE
Mark V. Dahl, MD
Harry J. Hurley, MD*
Peter J. Lynch, MD
Stephen W. Clark
John H. Epstein, MD
Paul M. Lazar, MD*
Cheryl K. Nordstedt
Edgar B. Smith, MD*
Mark A. Everett, MD*
Samuel L. Moschella, MD
Paul S. Russell, MD
Rex A. Amonette, MD
David R. Bickers, MD
Robert A. Briggaman, MD
Irwin M. Freedberg, MD*
Gloria F. Graham, MD
Richard B. Odom, MD
Richard K. Scher, MD
Fred F. Castrow II, MD
George W. Hambrick, Jr., MD*
Coleman Jacobson, MD*
A. Bernard Ackerman, MD*
Wilma F. Bergfeld, MD
Marshall L. Blankenship, MD*
Nancy B. Esterly, MD
Roy S. Rogers III, MD
Stephen B. Webster, MD
Marie-Louise Johnson, MD
Walter G. Larsen, MD
Jerome Z. Litt, MD
Lawrence A. Norton, MD*
W. Mitchell Sams, Jr., MD
Beverly B. Sanders, Jr., MD*
Alan R. Shalita, MD*
Frances J. Storrs, MD
Lynn A. Drake, MD
James D. Maberry, MD
Arthur L. Norins, MD
EXHIBIT HALL
1939
1949
1958
1968
1969
1989 1991 EDUCATION
2013
2014
2015
2016
2017
Mark V. Dahl, MD
Edgar B. Smith, MD*
Paul S. Russell, MD
Rex A. Amonette, MD
Coleman Jacobson, MD*
Stephen B. Webster, MD
Frances J. Storrs, MD
J. Graham Smith, Jr., MD*
Richard B. Odom, MD
C. William Hanke, MD, MPH
Alan R. Shalita, MD*
William D. James, MD
June K. Robinson, MD
Darrell S. Rigel, MD
David M. Pariser, MD
WELCOME
2002
2003
2004
2005
2006
2007
2008
2009
2011 2012 WELCOME TO THE 2017 AAD ANNUAL MEETING
THOMAS G PEARSON, ED.D,
MEMORIAL EDUCATION
AWARD
Mary E. Maloney, MD
Elizabeth I. McBurney, MD
Roy S. Rogers III, MD
Jean L. Bolognia, MD
Thomas L. Ray, MD
Jeffrey P. Callen, MD
Peter J. Lynch, MD
Maria L. Chanco Turner, MD
Christie Travelute, MD
Erik J. Stratman, MD
Timothy G. Berger, MD
Ilona J. Frieden, MD
Robert S. Kirsner, MD
Amit Garg, MD
Theodore Rosen, MD
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
John S. Strauss, MD*
Irwin M. Freedberg, MD*
M. Roy Schwarz, MD
Philip C. Anderson, MD*
Bradford W. Claxton, CAE
Edward A. Krull, MD*
Mark V. Dahl, MD
Captain Jeffrey G. Ashby
Lowell A. Goldsmith, MD
Klaus Wolff, MD
Marcus A. Conant, MD
Harry J. Hurley, MD*
Peyton E. Weary, MD*
Steven R. Feldman, MD, PhD
Antoinette F. Hood, MD
Barbara A. Gilchrest, MD
Roderick J. Hay, MD
James J. Leyden, MD
Neil S. Prose, MD
Darrell S. Rigel, MD
Michael E. Bigby, MD
Jack S. Resneck, Jr., MD
Bruce U. Wintroub, MD
Amy S. Paller, MD
Carrie L. Kovarik, MD
LILA GRUBER MEMORIAL
CANCER RESEARCH AWARD
AND LECTURESHIP
1972
1973
1974
1974
1975
1975
1976
1976
1977
1977
1978
1978
1979
1979
1980
1980
1981
1982
1982
1983
1983
Sol Spiegelman, PhD
Professor Jacques Monod*
Robert A. Good, MD, PhD
Judah Folkman, MD
H. Sherwood Lawrence, MD
K. Frank Austen, MD
Charles Heidelberger, PhD
James E. Cleaver, PhD
Frederic E. Mohs, MD*
Bert W. O’Malley, MD
Hermann Pinkus, MD*
Henry Kaplan, MD
Emil Frei III, MD
Gerald Weissmann, MD
Howard Green, MD
Eugene J. Van Scott, MD
Howard M. Temin, PhD
Werner Bollag, MD
Michael B. Sporn, MD
Stanley Cohen, PhD
Wallace Clark, Jr., MD*
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
EUGENE J VAN SCOTT
AWARD FOR INNOVATIVE
THERAPY OF THE SKIN AND
PHILLIP FROST LEADERSHIP
LECTURE
2008
2009
2010
2011
2012
2012
2013
2014
2015
2016
2017
Douglas R. Lowy, MD
John J. Voorhees, MD
R. Rox Anderson, MD
Anton Stuetz, PhD
Alastair Carruthers, MD
Jean D.A. Carruthers, MD
Jouni Uitto, MD, PhD
Ervin H. Epstein, Jr., MD
James G. Krueger, MD, PhD
Jeffrey A. Klein, MD
Christine Leaute-Labreze, MD
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013 2014
2015
2016
2017
Maria L. Chanco Turner, MD
Donald P. Lookingbill, MD
Irwin H. Braverman, MD
Rex A. Amonette, MD
Gloria F. Graham, MD
Jeffrey P. Callen, MD
Roy S. Rogers III, MD
Samuel L. Moschella, MD
William D. James, MD
Jean L. Bolognia, MD
Frances J. Storrs, MD
Libby Edwards, MD
Timothy M. Johnson, MD
Henry W. Lim, MD
Mark Lebwohl, MD
Timothy G. Berger, MD
James S. Taylor, MD
Harley A. Haynes, MD
Pearl E. Grimes, MD
MARION B SULZBERGER
INTERNATIONAL
LECTURESHIP
(Formerly Miles Pharmaceuticals
Lectureship)
Sponsored by Miles Pharmaceuticals
1965
Marion B. Sulzberger, MD*
1966
Eugene M. Farber, MD*
1967
Herman Beerman, MD*
1968
Walter C. Lobitz, Jr., MD*
1969
Carl T. Nelson, MD*
1970
Alfred W. Kopf, MD
1971
Richard K. Winkelmann, MD*
1972
Harvey Blank, MD*
1973
Walter B. Shelley, MD*
1974
Rees B. Rees, MD*
1975
Harry L. Arnold, Jr., MD*
1976
Rudolf L. Baer, MD*
1977
Robert W. Goltz, MD*
1978
Richard L. Dobson, MD
1979
Thomas B. Fitzpatrick, MD*
1980
Aaron B. Lerner, MD
1981
Hermann Pinkus, MD*
1983
Howard I. Maibach MD
1984
J. Graham Smith, Jr., MD*
1985
John H. Epstein, MD
1986
Harold O. Perry, MD*
1987
John S. Strauss, MD*
1988
Samuel L. Moschella, MD
1989
Irwin M. Braverman, MD
1990
Richard B. Odom, MD
1991
G. Thomas Jansen, MD*
1992
Edgar B. Smith, MD*
EVERETT C FOX, MD,
MEMORIAL LECTURESHIP
1994
1995
1996
1997
1998
Harry J. Hurley, MD*
G. Thomas Jansen, MD*
William M. Narva, MD
Victor D. Newcomer, MD*
Elizabeth I. McBurney, MD
NOTES
Stephen I. Katz, MD, PhD
Robert A. Briggaman, MD
Gerald S. Lazarus, MD
Douglas R. Lowy, MD
John A. Parrish, MD
Eugene A. Bauer, MD
Thomas T. Provost, MD*
Kirk D. Wuepper, MD*
David R. Bickers, MD
Jouni J. Uitto, MD
Thomas J. Lawley, MD
Luis A. Diaz, MD
Wilma F. Bergfeld, MD
Ervin H. Epstein, Jr., MD
Barbara A. Gilchrest, MD
Paul R. Bergstresser, MD
John R. Stanley, MD
R. Rox Anderson, MD
Robert L. Modlin, MD
Paul Khavari, MD, PhD
Michael J. Detmar, MD
Gary S. Wood, MD
Kim B. Yancey, MD
John A. McGrath, MD
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
Margaret L. Kripke, PhD
Robert C. Gallo, MD
J. Michael Bishop, MD
Harald Zur Hausen, MD
Thomas A. Waldmann, MD
Philip Leder, MD
Robert T. Schimke, MD
Stuart H. Yuspa, MD
Robert A. Weinberg, MD
Lance A. Liotta, MD
Arnold J. Levine, PhD
Erkki Ruoslahti, MD
Francis S. Collins, MD, PhD
Burt Vogelstein, MD
Edward E. Harlow, Jr., PhD
Mary-Claire King, PhD
Richard D. Klausner, MD
Alfred G. Knudson, MD
David M. Livingston, MD
Douglas R. Lowy, MD
Stanley Koesmeyer, MD
Eric S. Lander, PhD
Steven A. Rosenberg, MD, PhD
Carol W. Greider, PhD
Errol C. Friedburg, MD
Ian H. Frazer, MD
John Mendelsohn, MD
Michael R. Stratton, MD
William Marston Linehan, MD
Elizabeth Blackburn, PhD
Martin A. Weinstock, MD, PhD
Lynda Chin, MD
Antoni Ribas, MD, PhD
Paul A. Khavari, MD, PhD
Boris C. Bastian, MD, PhD
CITY GUIDE
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
CLARENCE S LIVINGOOD,
MD, AWARD AND
LECTURESHIP
1984
1984
1985
1985
1986
1987
1988
1989
1990
1991
1992
1993
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
MAPS
MARION B SULZBERGER,
MD, MEMORIAL AWARD
AND LECTURESHIP
(Lila Gruber Fund Award of the
AAD)
Kevin D. Cooper, MD
Andrzej A. Dlugosz, MD
Thomas S. Kupper, MD
Richard L. Gallo, MD, PhD
Hensin Tsao MD, PhD
Anthony E. Oro, MD, PhD
George Cotsarelis, MD
Gil Yosipovitch, MD
Joel M. Gelfand, MD
EXHIBIT HALL
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2009
2010
2011
2012
2013
2014
2015
2016
2017
EDUCATION
Frances J. Storrs, MD
A. Bernard Ackerman, MD*
Stephen I. Katz, MD, PhD
Mark V. Dahl, MD
Jon M. Hanifin, MD
Nancy Esterly, MD
Edward A. Krull, MD*
John J. Voorhees, MD
James J. Nordlund, MD
Wilma F. Bergfeld, MD
Howard I. Maibach, MD
Barbara A. Gilchrest, MD
Roy S. Rogers III, MD
Walter Burgdorf, MD*
Jeffrey P. Callen, MD
WELCOME
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013 2014
2015
2016
2017
* Indicates deceased members
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
aad.org 23
IMPORTANT SAFETY
INFORMATION
mood changes, and they should contact their
healthcare provider if such changes occur
– Treatment with Otezla is associated with
Contraindications
an increase in adverse reactions of
◆ Otezla® (apremilast) is contraindicated in
depression. During clinical trials, 1.3%
patients with a known hypersensitivity to
(12/920) of patients treated with Otezla
apremilast or to any of the excipients in
reported depression compared to 0.4%
(2/506) on placebo; 0.1% (1/1308) of Otezla
the formulation
patients discontinued treatment due to
Warnings and Precautions
depression compared with none on
◆ Depression: Carefully weigh the risks and
placebo (0/506). Depression was reported
benefits of treatment with Otezla for
as serious in 0.1% (1/1308) of patients
patients with a history of depression and/or exposed to Otezla, compared to none in
suicidal thoughts/behavior, or in patients
placebo-treated patients (0/506). Suicidal
who develop such symptoms while on
behavior was observed in 0.1% (1/1308) of
Otezla. Patients, caregivers, and families
patients on Otezla, compared to 0.2%
should be advised of the need to be alert
(1/506) on placebo. One patient treated
for the emergence or worsening of
with Otezla attempted suicide; one
patient on placebo committed suicide
depression, suicidal thoughts or other
Otezla® is a registered trademark of Celgene Corporation.
© 2017 Celgene Corporation 01/17 USII-APR160428a
Weight Decrease: Monitor body weight
regularly; evaluate unexplained or clinically
significant weight loss, and consider
discontinuation of Otezla. Body weight loss
of 5-10% occurred in 12% (96/784) of patients
treated with Otezla and in 5% (19/382) of
patients treated with placebo. Body weight
loss of ≥10% occurred in 2% (16/784) of
patients treated with Otezla compared to
1% (3/382) of patients treated with placebo
◆ Drug Interactions: Apremilast exposure
was decreased when Otezla was
co-administered with rifampin, a strong
CYP450 enzyme inducer; loss of Otezla
efficacy may occur. Concomitant use of
Otezla with CYP450 enzyme inducers (eg,
rifampin, phenobarbital, carbamazepine,
phenytoin) is not recommended
◆
References: 1. Otezla [package insert]. Summit, NJ: Celgene Corporation; 2015. 2. Data on file, Celgene
Corporation. 3. Papp K, Reich K, Leonardi CL, et al. J Am Acad Dermatol. 2015;73(1):37-49.
STUDY DESIGN
◆
Otezla was evaluated in 2 multicenter, double-blind, placebo-controlled trials
of similar design. Patients with moderate to severe plaque psoriasis (N = 1257)
were randomized 2:1 to Otezla 30 mg or placebo twice daily for 16 weeks, after
a 5-day titration1,3
Adverse Reactions
◆
Adverse reactions reported in ≥5% of
patients were (Otezla%, placebo%): diarrhea
(17, 6), nausea (17, 7), upper respiratory tract
infection (9, 6), tension headache (8, 4), and
headache (6, 4)
Use in Specific Populations
◆
Pregnancy and Nursing Mothers: Otezla is
◆
Inclusion criteria: Age ≥18 years, BSA involvement ≥10%, sPGA ≥3,
PASI score ≥12, candidates for phototherapy or systemic therapy1,3
◆
Results were similar between ESTEEM 1 and ESTEEM 21,2
BSA, body surface area; PASI, Psoriasis Area and Severity Index; ScPGA, Scalp Physician
Global Assessment; sPGA, static Physician Global Assessment.
Pregnancy Category C; it has not been
studied in pregnant women. Use during
pregnancy only if the potential benefit
justifies the potential risk to the fetus.
It is not known whether apremilast or its
metabolites are present in human milk.
Caution should be exercised when Otezla
is administered to a nursing woman
a
Results were consistent between ESTEEM 1 and ESTEEM 2. b Week 16: secondary endpoint; all other timepoints: exploratory
endpoints. c Baseline mean PASI scores: Placebo, 19; Otezla, 19; Total, 19. d During weeks 16 through 32 (maintenance phase), all
patients received Otezla. e Causes of patient dropout include adverse events, lack of efficacy, and patient withdrawal. f 95%
confidence interval. g FAS; LOCF. h Week 16: Prespecified exploratory endpoint. In the planned hierarchical statistical testing
sequence for ESTEEM 1 and ESTEEM 2, efficacy analyses preceding ScPGA were statistically significant, allowing for control
of the overall type 1 error rate at 0.05 significance level in analysis of ScPGA. i Baseline ScPGA ≥3.
Get the latest news at otezlapro.com
◆
Renal Impairment: Otezla dosage should
be reduced in patients with severe renal
impairment (creatinine clearance less
than 30 mL/min); for details, see Dosage
and Administration, Section 2, in the Full
Prescribing Information
Please turn the page for Brief Summary
of Full Prescribing Information.
Rx Only
OTEZLA® (apremilast) tablets, for oral use
The following is a Brief Summary; refer to Full Prescribing Information for
complete product information.
INDICATIONS AND USAGE
OTEZLA® (apremilast) is indicated for the treatment of patients with moderate
to severe plaque psoriasis who are candidates for phototherapy or systemic
therapy.
CONTRAINDICATIONS
OTEZLA is contraindicated in patients with a known hypersensitivity to apremilast
or to any of the excipients in the formulation [see Adverse Reactions (6.1)].
WARNINGS AND PRECAUTIONS
Depression: Treatment with OTEZLA is associated with an increase in adverse
reactions of depression. Before using OTEZLA in patients with a history of
depression and/or suicidal thoughts or behavior prescribers should carefully
weigh the risks and benefits of treatment with OTEZLA in such patients.
Patients, their caregivers, and families should be advised of the need to be alert
for the emergence or worsening of depression, suicidal thoughts or other mood
changes, and if such changes occur to contact their healthcare provider.
Prescribers should carefully evaluate the risks and benefits of continuing
treatment with OTEZLA if such events occur. During the 0 to 16 week placebocontrolled period of the 3 controlled clinical trials, 1.3% (12/920) of patients
treated with OTEZLA reported depression compared to 0.4% (2/506) treated
with placebo. During the clinical trials, 0.1% (1/1308) of patients treated with
OTEZLA discontinued treatment due to depression compared with none in
placebo-treated patients (0/506). Depression was reported as serious in 0.1%
(1/1308) of patients exposed to OTEZLA, compared to none in placebo-treated
patients (0/506). Instances of suicidal behavior have been observed in 0.1%
(1/1308) of patients while receiving OTEZLA, compared to 0.2% (1/506) in
placebo-treated patients. In the clinical trials, one patient treated with OTEZLA
attempted suicide while one who received placebo committed suicide.
Weight Decrease: During the controlled period of the trials in psoriasis, weight
decrease between 5%-10% of body weight occurred in 12% (96/784) of patients
treated with OTEZLA compared to 5% (19/382) treated with placebo. Weight
decrease of ≥10% of body weight occurred in 2% (16/784) of patients treated
with OTEZLA 30 mg twice daily compared to 1% (3/382) patients treated with
placebo. Patients treated with OTEZLA should have their weight monitored
regularly. If unexplained or clinically significant weight loss occurs, weight loss
should be evaluated, and discontinuation of OTEZLA should be considered.
Drug Interactions: Co-administration of strong cytochrome P450 enzyme
inducer, rifampin, resulted in a reduction of systemic exposure of apremilast,
which may result in a loss of efficacy of OTEZLA. Therefore, the use of
cytochrome P450 enzyme inducers (e.g., rifampin, phenobarbital, carbamazepine,
phenytoin) with OTEZLA is not recommended [see Drug Interactions (7.1) and
Clinical Pharmacology (12.3)].
ADVERSE REACTIONS
Clinical Trials Experience in Psoriasis: Because clinical trials are conducted
under widely varying conditions, adverse reaction rates observed in the clinical
trial of a drug cannot be directly compared to rates in the clinical trials of another
drug and may not reflect the rates observed in clinical practice. Diarrhea,
nausea, and upper respiratory tract infection were the most commonly reported
adverse reactions. The most common adverse reactions leading to discontinuation
for patients taking OTEZLA were nausea (1.6%), diarrhea (1.0%), and headache
(0.8%). The proportion of patients with psoriasis who discontinued treatment
due to any adverse reaction was 6.1% for patients treated with OTEZLA 30 mg
twice daily and 4.1% for placebo-treated patients.
Table 3: Adverse Reactions Reported in ≥1% of Patients on OTEZLA and With
Greater Frequency Than in Patients on Placebo; up to Day 112 (Week 16)
Preferred Term
Placebo
(N=506)
n (%)
OTEZLA 30 mg BID
(N=920)
n (%)
Diarrhea
32 (6)
160 (17)
Nausea
35 (7)
155 (17)
Upper respiratory tract infection
31 (6)
84 (9)
Tension headache
21 (4)
75 (8)
Headache
19 (4)
55 (6)
Abdominal pain*
11 (2)
39 (4)
Vomiting
8 (2)
35 (4)
Fatigue
9 (2)
29 (3)
(continued)
Table 3: Adverse Reactions Reported in ≥1% of Patients on OTEZLA and With
Greater Frequency Than in Patients on Placebo; up to Day 112 (Week 16)
Placebo
(N=506)
n (%)
OTEZLA 30 mg BID
(N=920)
n (%)
Dyspepsia
6 (1)
29 (3)
Decrease appetite
5 (1)
26 (3)
Insomnia
4 (1)
21 (2)
Back pain
4 (1)
20 (2)
Migraine
5 (1)
19 (2)
Frequent bowel movements
1 (0)
17 (2)
Depression
2 (0)
12 (1)
Bronchitis
2 (0)
12 (1)
Tooth abscess
0 (0)
10 (1)
Folliculitis
0 (0)
9 (1)
Sinus headache
0 (0)
9 (1)
Preferred Term
*Two subjects treated with OTEZLA experienced serious adverse reaction of
abdominal pain.
Severe worsening of psoriasis (rebound) occurred in 0.3% (4/1184) patients
following discontinuation of treatment with OTEZLA (apremilast).
DRUG INTERACTIONS
Strong CYP 450 Inducers: Apremilast exposure is decreased when OTEZLA is
co-administered with strong CYP450 inducers (such as rifampin) and may
result in loss of efficacy [see Warnings and Precautions (5.3) and Clinical
Pharmacology (12.3)].
USE IN SPECIFIC POPULATIONS
Pregnancy: Pregnancy Category C : OTEZLA should be used during pregnancy
only if the potential benefit justifies the potential risk to the fetus. Pregnancy
Exposure Registry: There is a pregnancy exposure registry that monitors
pregnancy outcomes in women exposed to OTEZLA during pregnancy.
Information about the registry can be obtained by calling 1-877-311-8972.
Nursing Mothers: It is not known whether OTEZLA or its metabolites are present
in human milk. Because many drugs are present in human milk, caution should
be exercised when OTEZLA is administered to a nursing woman. Pediatric use:
The safety and effectiveness of OTEZLA in pediatric patients less than 18 years
of age have not been established. Geriatric use: Of the 1257 patients who
enrolled in two placebo-controlled psoriasis trials (PSOR 1 and PSOR 2), a total
of 108 psoriasis patients were 65 years of age and older, including 9 patients
who were 75 years of age and older. No overall differences were observed in the
efficacy and safety in elderly patients ≥65 years of age and younger adult
patients <65 years of age in the clinical trials. Renal Impairment: Apremilast
pharmacokinetics were characterized in subjects with mild, moderate, and
severe renal impairment as defined by a creatinine clearance of 60-89, 30-59,
and less than 30 mL per minute, respectively, by the Cockcroft–Gault equation.
While no dose adjustment is needed in patients with mild or moderate renal
impairment, the dose of OTEZLA should be reduced to 30 mg once daily in
patients with severe renal impairment [see Dosage and Administration (2.2) and
Clinical Pharmacology (12.3)]. Hepatic Impairment: Apremilast pharmacokinetics
were characterized in patients with moderate (Child Pugh B) and severe (Child
Pugh C) hepatic impairment. No dose adjustment is necessary in these patients.
OVERDOSAGE
In case of overdose, patients should seek immediate medical help. Patients
should be managed by symptomatic and supportive care should there be an
overdose.
Manufactured for: Celgene Corporation, Summit, NJ 07901
OTEZLA® is a registered trademark of Celgene Corporation.
Pat. http://www.celgene.com/therapies
©2015 Celgene Corporation, All Rights Reserved.
Based on APRPI.005
OTZ_PsO_HCP_BSv.004 12_2015
EDUCATIONAL OPPORTUNITIES
Poster Presentation Centers
LOCATION: HALL B4, SECOND LEVEL
e-Posters
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
NOTES
AAD e-Posters are searchable by category.
Find posters by searching:
•Acne
• Aesthetic Dermatology
•Aging/Geriatrics
• Arts, History, & Humanities of
Dermatology
• Basic Science
• Clinical Dermatology & Other
Cutaneous Disorders
CITY GUIDE
A full listing of the posters and a schedule
of presentations is available at aad.org/
eposters/view, on the AAD Meeting
Mobile App, and on-site at the Orange
County Convention Center.
• Connective Tissue Diseases
• Dermatitis, Contact, Allergic & Irritant
• Dermatitis, Atopic
•Dermatopathology
• Digital/Electronic Technology
• Education & Community Service
• Epidemiology & Health Services
Administration
•Genodermatoses
• Hair & Nail Disorders
• Immunodermatology & Blistering
Disorders
• Infection – Bacterial & Parasitic
• Infection – Fungal
• Infection – Viral
• Internal Medicine Dermatology
• Lymphoma, Cutaneous/Mycosis
Fungoides
• Melanoma & Pigmented Lesions
• Non-melanoma Skin Cancer
• Pediatric Dermatology
•Pharmacology
• Photobiology, Phototherapy &
Photosensitivity Diseases
• Pigmentary Disorders & Vitiligo
• Psoriasis & Other Papulosquamous
Disorders
• Surgery – Laser
• Surgery – Cosmetic
• Surgery – Dermatologic
• Wound Healing & Ulcers
MAPS
The Poster Presentation Centers will
comprise of three separate viewing areas,
as well as a hub of computers where
attendees can search and view posters at
any time.
EXHIBIT HALL
Friday..................................... 7 a.m.-5 p.m.
Saturday................................. 7 a.m.-5 p.m.
Sunday .................................. 7 a.m.-5 p.m.
Monday.................................. 7 a.m.-5 p.m.
EDUCATION
Poster exhibit hours
WELCOME
POSTER
information
aad.org 27
EDUCATIONAL OPPORTUNITIES
Educational
HIGHLIGHTS
PLENARY SESSION
SUNDAY, 8-11:30 A.M.
LOCATION: CHAPIN THEATER
8:50 a.m.
Carrie L. Kovarik, MD, FAAD
Telemedicine and the Future
of Medicine
Dermatology will continue to face challenges as
new models for health care
delivery systems evolve and
value-based care becomes
implemented on a wider scale.
Teledermatology has the potential to improve
access for patient care within these health
care systems and provide an efficient,
patient-centered experience. Teledermatology
can be used to improve patient care, access,
and outcomes in a variety of ways, including
triage, urgent care, inpatient consultation,
direct follow-up with patients, and patient
monitoring, when integrated into the patients’
overall medical care. Recommendations for
standard ethical practices in teledermatology
are essential in order to ensure consistent
coordinated, high-quality care. We are
currently at a crossroads where technology,
medical care, patient needs, business success,
and free market competition are in occasional
opposition and imbalance. The position of
our specialty and future of medicine will be
determined by how the advocates of these
opposing forces work together.
Experience AAD in Orlando
10:35 a.m.
Joel M. Gelfand, MD, MSCE, FAAD
Eugene J. Van Scott Award for Innovative
Therapy of the Skin and Phillip Frost
Leadership Lecture
Marion B. Sulzberger, MD, Memorial Award
and Lectureship
Propranolol in Infantile Hemangiomas:
A Successful Drug Repurposing
Clarence S. Livingood, MD, Award and
Lectureship
28
9:30 a.m.
Christine Léauté-Labrèze, MD
In 2014, propranolol was the first treatment approved to
treat complicated infantile
hemangiomas. The effect was
first observed in an infant
treated with propranolol for
corticosteroid-induced myocardiopathy. The
step from a serendipitous observation of the
therapeutic effect to the voluntary
administration to ensure the reproducibility
was easy to make because there was no
satisfactory treatment for infantile
hemangiomas. Dr. Léauté-Labrèze will
explain how a well-known molecule used in
cardiology for 50 years has been developed
with success in an unexpected indication.
10:10 a.m.
Boris C. Bastian, MD, PhD
Lila and Murray Gruber Memorial Cancer
Research Award and Lectureship
How Moles Become Cancer
The lecture will cover recent research on the molecular
evolution of melanomas from
their corresponding precursor
lesions and provide a
summary of the molecular
taxonomy of melanocytic neoplasms.
Getting to the Heart (and Other
Co-morbidities) of Psoriasis
Psoriasis is a chronic Th1, Th17 inflammatory
disease of the skin and joints.
Emerging research ranging
from large, broadly
representative populationbased studies, to smaller, deeply phenotyped,
specialty clinic-based studies, to experimental
animal models, indicate that psoriasis is
associated with major cardiovascular events,
disorders of metabolism, diabetes, end-stage
renal disease, and mortality. It ultimately
culminates in approximately five years of life
lost among patients with more severe skin
disease. Emerging observational and
experimental studies in humans are better
defining the impact of systemic treatment of
psoriasis on major health outcomes such as
major cardiovascular events. These scientific
advances have important clinical implications
for the care of patients with psoriasis and
have resulted in changes to standard of care
recommendations.
11:00 a.m.
RADM Jordan W. Tappero, MD, MPH
Guest Speaker
The West African Ebola Epidemic and
the Global Health Security Agenda
As Senior Advisor for Global Health, Center for
Global Health (CGH), Centers
for Disease Control and
Prevention (CDC), Dr. Tappero
provides strategic scientific and
programmatic contributions to the Office of the
Director’s (CGH/OD) management and
oversight of a more than $3 billion annual
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
EDUCATIONAL OPPORTUNITIES
INDUSTRY EXPERT
SESSIONS
These unique sessions provide exhibiting
companies the opportunity to present
new research findings on products, detail
products, conduct demonstrations, and
highlight new products. These sessions are
solely promotional, and are not eligible for
continuing medical education credit.
11-11:45 a.m.
Moving Beyond Topicals: Perspectives
on Systemic Treatment for Psoriasis
This is an unbranded program in which
Shane Chapman, MD, will be discussing the
unmet needs for psoriasis patients, limitations
of topical-only treatment and considerations
for transitioning patients from a topical to a
systemic therapy.
Hosted by: Celgene
Jeffrey Sobell, MD, will be presenting a
current oral, non-biologic treatment option in
moderate to severe plaque psoriasis.
Hosted by: Celgene
Hosted by: Allergan
SATURDAY
11-11:15 a.m.
Cosentyx
Novartis Pharmaceuticals is dedicated to
discovering, developing, manufacturing, and
marketing prescription drugs that help meet
our customers’ medical needs and improve
their quality of life.
Hosted by: Regeneron and Sanofi Genzyme
1:30-2:15 p.m.
Cosentyx
Novartis Pharmaceuticals is dedicated to
discovering, developing, manufacturing, and
marketing prescription drugs that help meet
our customers’ medical needs and improve
their quality of life.
Hosted by: Novartis
2:45-3:30 p.m.
Spotlight on CIU: Vicki Lawrence’s Story
Actress and comedienne Vicki Lawrence will
share her experience with chronic idiopathic
urticaria (CIU), a form of chronic hives. She
is the face of CIU & You, a program focused
on supporting CIU patients’ needs. Vicki
will be joined by a leading dermatologist to
discuss CIU and disease management
Hosted by: GENENTECH/NOVARTIS
SUNDAY
11-11:45 a.m.
Introducing a new nonsteroidal topical
prescription treatment option for
mild-to-moderate atopic dermatitis
Hosted by: Amgen
1:30-2:15 p.m.
IL-23 BIOLOGY AND ITS ROLE IN THE
PATHOGENESIS OF PSORIASIS
The TH17 immunologic pathway, and
associated cytokines, have a fundamental role
in the pathophysiology of psoriasis. IL-23
is required for the maturation of TH17 cells
and, consequently, production of IL-17 and
IL-22. Several IL-23 inhibitor therapies are
in development; their mechanism of action
and anticipated clinical outcomes will be
discussed.
Hosted by: SUN Dermatology
SYMPOSIA HIGHLIGHTS
FRIDAY
9 a.m.-12 p.m.
Location: Chapin Theater
S004 – Therapeutic Hotline
SATURDAY
1-4 p.m.
Location: Chapin Theater
S024 – Hot Topics
SUNDAY
Come learn about a new, nonsteroidal
treatment option for patients aged 2 years
and older with mild-to-moderate atopic
dermatitis. We’ll review the mechanism of
action and the efficacy and safety data.
1-4 p.m.
Location: Chapin Theater
S038 – Psoriasis
Hosted by: Pfizer
8-10 a.m.
Location: Room 415A
S068 – Therapeutic and Diagnostic Pearls
TUESDAY
CITY GUIDE
1:30-2:15 p.m.
Allergan Medical Dermatology
Expert faculty will highlight advances in
development of biosimilars for psoriasis,
review the totality of evidence supporting
biosimilar approval, and discuss the unique
considerations for clinical evaluation of a
biosimilar.
MAPS
12:15-1 p.m.
You’ve Got Options: The Changing
Paradigm of Plaque Psoriasis Treatment
Atopic dermatitis is a common, chronic
inflammatory skin disease. Current evidence
demonstrates nonlesional skin is abnormal
with persistent subclinical inflammation
throughout the body. Underlying chronic
inflammation leads to well-known AD signs
and symptoms. Type 2 (including Th2)
cytokines, IL-4 and IL-13, are key drivers of
this inflammatory process.
EXHIBIT HALL
FRIDAY
12:15-1 p.m.
Biosimilars in Psoriasis: Insights Into the
Evidence evaluation of a biosimilar
EDUCATION
LOCATION: EXHIBIT HALL
12:15-1 p.m.
In Atopic Dermatitis, Looks Can be
Deceiving
WELCOME
budget. He also leads and executes CGH/OD’s
efforts to institutionalize the Global Health
Security Agenda at CDC. He brings 24 years of
extensive global experience to this key leadership
position, including 11 years residing overseas.
10:30 a.m.-12:30 p.m.
Location: Room 415A
S069 – What’s New in Dermatology
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
NOTES
Hosted by: Novartis
aad.org 29
THE BEST SOLUTION IS
ONE SOLUTION
PATENT PENDING
CLINICALLY PROVEN
ROZATROL™
Treatment For Red, Sensitized Skin
Nearly 80% of rosacea patients reported
having to use more than one medication to
manage the condition.*
Rozatrol™ features a multiplex of ingredients
to relieve the multiple symptoms known to
be associated with rosacea. All in One Tube.
BASELINE
6 WEEKS
BASELINE
6 WEEKS
Decrease in severity of rosacea, flushing and redness symptoms at six weeks.
zoskinhealth.com
VISIT US AT BOOTH #2069
*Independent third party study of 22 subjects to assess the efficacy potential of Rozatrol™ in minimizing
the signs and symptoms of Rosacea. Subjects were evaluated at 2, 4, and 6 weeks with the following
protocol AM and PM: Oilacleanse™, Rozatrol™ and Oclipse-C™ SPF 50 in the AM. *Source: National
Rosacea Society Survey
ALWAYS BE IN
THE KNOW WITH
THE MOBILE APP.
Use the app to find
the most up-to-date
information about
the 2017 AAD
Annual Meeting.
Cold Sore
Goodbye, cold sore.
Hello, beautiful.
Naturally, you want a cold sore to go
away fast. Naturally, it can. The
secret? Sarracenia. A plant-based
SuperBotanical™ that’s been proven
to work wonders. Aubio’s exclusive
formula works fast to get you back to
your beautiful, smiling self. How
fast? In a recent study, 100% of
Aubio cold sore gel users said
they’d use it again. That fast.
This year, the app is redesigned to provide
optimum functionality and ease of navigation.
Features include:
• Session schedule
•Exhibitors
•Speakers
•Maps
• Event listings
•e-Posters
• Audience Response
sessions
• Frequently asked
questions
Download the app now in the iPhone App Store
or on Google Play.
aubío.com
Nature’s golden drop.™
WF
WA1
1193
1092
1090
1091
1088
1182
1183
1282
1081
1180
1181
1085
1082
1080
Room
Room 660
Room 656
Room 652
1070
1071
1175
Room 644
Room 640
Room 636
Room 632
1275
1476
1375
1474
1475
1577
1676
1575
1674
1270
1170
1469
1169
1266
1065
1165
1264
1367
1366
1569
1668
1567
1666
2078
1360
1675
1774
1775
1671
1770
1771
1768
1769
1766
1767
1667
1974
1875
2379
1975
2074
2174
2075
2177
2276
2175
2274
2275
2271
1969
1866
2370
2474
2371
2470
2675
2575
2475
2981
3586
3587
3081
3381
2875
2775
2975
3074
3075
3175
3481
2969
2565
2064
2664
3269 3368
3169
3068
3369
3264
2665
3063
3163
3161 3260
2461
3365
3464
3363
3462
3261
1353
1253
1053
1040
1553
1661
1653
1953
2053
1241
1041
2453
2253
2953
2753
2553
3153
3567
3564
3563
3461
3458
3459
3558
3453
3559
AAD
CONNECTION
3553
1026
1432
1133
1031
1130
1029
1128
1027
1126
1433
1127
1327
1120
1019
1118
1016
1017
1116
1014
1015
1114
1012
1013
2431
2231
1930
1426
1427
1527
1626
1627
2027
1927
1719
1619
1319
2530
2127
2226
2227
2326
2327
3134
3031
3130
3435
2623 2722
2827
2723 2822
3127
2922
2923
3327
3022
1819
2319
2219
2019
1919
3221
3320
3219
3318
3015
3215
3211
1110
1205
1505
1305
2405
2005
1605
EXIT
EXIT
WF
FX
L2-09
10'
B
16'-6"
L2-09A
SEATING AREA
TILED FLOOR AREA
27'
39'2"
10'-8"
11'-4"
L2-15A
19'
10'
B
L2-15
L2-13
HALL WA4 ENTRANCE
L2-17
10'
TILED FLOOR AREA
19'
A
16'-6"
L2-17B
10'
FX
SEATING AREA
39'2"
10'
10'-8"
TILED FLOOR AREA
L2-24A
10'
B
L2-24
18'-6"
DO NOT
BLOCK
L2-12
@75.75"
EXIT
ENTRANCE
HALL WA3 ENTRANCE
FX
2805
2505
3314
3523
3520
3315
3414
3313
3412
34'
10'
L2-21
NOT
MEASURED
(HAD MIS WRAP)
EXIT
EXIT
L2-19
L2-20B
3518
3519
3515
3413
3513
3410
3310
3205
3005
3305
3406
3407
3404
3405
3508
3509
3504
3505
0001
2000
BOOTHS 3022-3591
BOOTHS 2060-2989
WF
WF
FX
EXIT
CK
WF
R
FX
3423
3408
1304
WF
FX
EXIT
3527
3419
1207
1105
3427 3526
3321
1308
1005
3531
3416
1313
1213
3533
3530
2417
L2-06
L2-07
2727
2527
2426
1515
1115
PLANTER
@76"
3035
1521
1219
PLANTER
EXIT
2835
3528
FX
EXIT
2834
1529
1121
1006
1004
2735
3333
1831
2523 2622
1021
3541
1533
1329
3545
3537
2635
2535
2435
2135
2035
1331
1231
(e-Posters and
Presentations,
AAD Resource
Center,
Networking
Center/e-Center)
3543
3041
2741
2536
1937
1635
1335
1032
B
3566
FX
3239
1036
1030
L2-04
3465
3460
3353
1539
1439
1339
2541
2441
2041
1038
733
L2-04A
3571
3445 3544
1035
10'-8"
3570
3343
INDUSTRY
EXPERT
SESSIONS
10'
3575
3469
3267 3366
2867
2767
3471
1044
FX WF
3581
3475
3271
2963 3062
2060
3375
2971
FX
WF
EXIT
ENTRANCE
FX
WF
EXIT
EXIT
ENTRANCE
EXIT
FX
FX
L2-28A
76'
10'
L2-28B
10'
10'-7"
SEATING AREA
39'TILED FLOOR AREA
46'-4"
L2-25A
10'
L2-25B
FX
EXIT
EXIT
HALL WB4 ENTRANCE
L2-39
L2-32
L2-22
WF
ENTRANCE
HALL WB2 & WB3 ENTRANCE
HALL WB1 ENTRANCE
L2-20C
-01B
3487
3557
1011
SEATING AREA
TILED FLOOR AREA
3486
1054
1008
10'
3387
3359
HALL WA2 ENTRANCE
16'-6"
3589
3386
3583
2880
2069
L2-20A
L2-01A
@75.625"
3588
1056
1020
PLANTER
HALL WA1 ENTRANCE
3591
3489
3579
1023
WF FX
EXIT
2781
2567
1961
3590
3488
3585
1662
1960
3287
3491
3389
2883
2683
2680
3286
3391
1058
1052
FX
EXIT
2884
3187
3390
3388
2478
1966
1867
2785
3188
EXIT
EXIT
5'5"
10'
For the most current, up-to-date information, go to aad.org/AM17 orL2-40
download the AAD Meeting Mobile App.
FX
L2-33
27'
10'
10'
10'
10'
30'-8"
39'
30'
10'-7"
L2-37A 46'-5"
L2-37B
SEATING AREA
TILED FLOOR AREA
NOTES
EXIT
2581
2375
BOOTHS 1605-1978
FX
2583
2483
2886
3089
2977
1870
1461
1361
2178
2079
1877
1965
1261
1060
1978
1778
1265
1563
2482
2381
1679
1377
2383
1581
1062
PRIVATE EXPO MEETING SUITES
Room 545
Room 541
Room 537
Room 533
Room 628
Room 620
Room 616
Room 612
Room 608
Room 604
Room 529
Room 521
Room 517
Room 513
Room 509
Room 505
Room 544
Room 540
Room 536
Room 532
Room 528
Room 520
Room 516
Room 512
Room 508
1481
1381
1281
1274
1783
1683
2787
2989
CITY GUIDE
Room 504
FOOD COURT
3291
3191
2889
2589
2489
2389
3493
FX
Room 569
Room 565
Room 561
Room 557
Room 553
1075
2791
1788
1386
1278
1074
1689
PLANTER
Room 568
Room 564
Room 560
Room 556
Room 552
Room 668
Room 469
Room 465
Room 461
Room 457
Room 453
Room 445
Room 441
Room 437
Room 433
Room 429
1688
FX
MAPS
Room 421
1589
3492
3293
MAPS HELP YOU FIND YOUR WAY
FHC
EXHIBIT HALL
Room 417
1489
1389
3192
WB4
FX
FHC
1693
1691
1591
1390
1177
1068
2018
SPACE
SELECTION
OFFICE
1692
2684
1066
Room 413
1287
1083
1084
1076
Room 409
1289
1286
1078
Room 405
1291
1187
1087
1064
1290
1288
1186
1086
1593
1293
WB2 WB3
FX
PLANTER
EXHIBITS
WB1
FHC
EDUCATION
X
WA4
FHC
FHC
WELCOME
FX WF
WA3
FHC
▲
HB
WA2
Floor plan current as of Jan. 25, 2017.
AAD 2017 EXHIBIT HALL FLOOR PLAN
FHC
✓
✓
✓
✓
✓
EXPERIENCE • EXPLORE • INTERACT
at the
AAD Resource Center in Hall B4
Friday, March 3 – Monday, March 6
8 a.m. – 5 p.m. daily
WHAT’S NEW
•
•
•
SHOP & SAVE
Come take your #AAD17 selfie!
The first 200 attendees to post get a
FREE selfie stick.
•
•
Discover AAD’s Practice Management
Center which features the latest
resources designed to help you navigate
the ever-changing practice environment.
•
Pre-order and save $50 on the 2017
Annual Meeting On-Demand Recordings.
•
20% off one AAD product, see coupon below.
FREE professional headshots.
10% off select AAD products.
Receive $50 off your 2017 MIPS reporting
plus a FREE gift with DataDerm™
enrollment.
HEADSHOT SCHEDULE:
Friday, March 3
Saturday, March 4
Sunday, March 5
Monday, March 6
•
10 a.m. – 5 p.m.
10 a.m. – 5 p.m.
12 p.m. – 5 p.m.
10 a.m. – 5 p.m.
Don’t forget our expert staff and
Affinity Partners will be on-hand to
assist you.
SAVE AT THE AAD RESOURCE CENTER
Present this coupon and get
20% OFF
ONE AAD PRODUCT *
*Offer only valid at the AAD Resource Center 3/3/2017 – 3/6/2017.
Present this coupon at time of purchase. Coupon may only be used once
and cannot be used on already discounted or previously purchased items.
Discount excludes taxes, shipping and handling, meeting registration,
membership dues, DermCare Team enrollment fees, JAAD subscription and
third-party products. AMRC17
✓
EXPLORE THE EXHIBIT HALL
Data current as of Feb. 1, 2017.
ALPHABETICALLY
WELCOME
Exhibitors
EDUCATION
EXHIBIT HALL
123
21st Century Oncology
3Gen Inc./DermLite
5CC (5-Continent-Congress)
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
aad.org 33
NOTES
Biodermis
2431, 3293
Biofrontera Inc.
3579
Biogenix Skin Sciences
1186
Biologica Technologies
1040
Biomed Diagnostics
3388
Biopelle Inc.
1919
BioPharmX3390
Bios SRL
1390
bioskin GmbH
1261
Blaine Labs Inc.
3416
Bloq-UV1691
Boehringer Ingelheim
Pharmaceuticals Inc.
3527
Bovie Medical
2371
brandMD Skin Care
3453
Brazilian Society for Dermatological
Surgery2475
Brymill Cryogenic Systems
2226
BTL1133
Cabana Life
3543
Caliber Imaging & Diagnostics
1866
Canfield Scientific
1927
Capillus LLC
2683
CareCredit1127
CarePath Diagnostics
1768
Carismed GmbH
1071
Castle Biosciences Inc.
1110
Celgene Corp.
1053
Centura Pharmaceuticals Inc.
1064
Chemistry Rx
2884
Chemotechnique Diagnostics/
Dormer Laboratories
1662
Cipher Pharmaceuticals Inc.
1683
CITY GUIDE
AbbVie
2053, 2441
Accredo2178
Accurate Manufacturing Inc.
3271
AccuTEC Blades
1965
AccuVein1070
Aclaris Therapeutics Inc.
3526
Actelion Pharmaceuticals US
2664
Action Bag Co.
1766
Acuderm2219
AD Surgical
1692
Adako USA
3187
Advalight1679
Advanced Dermatology & Cosmetic
Surgery3215
Advanced MD Inc.
2177
Advanced Rad Solutions
1058
Advanced Skin & Hair
1360
Advanced Technology Laser Co. Ltd.
3192
Aerolase1521
Aesthetic Guide, The
1335
Agnes formerly Gowoonsesang
Cosmetics1265
Allergan2253
Allied Powers LLC
3389
Allina Health
3588
Alma Lasers
2461
Alphaeon Corp.
1666
American Board of Dermatology
3134
American College of Phlebology
3491
American Society for Dermatologic
Surgery2426
American Society for Mohs Surgery
2723
Amgen Inc.
2553
AMP Medical Products LLC
3412
Anne Arundel Dermatology, P.A.
3391
AnteAGE MD by Cellese
1081
Anthony Products/Gio Pelle
3305
Anutra Medical
3558
AP Easy Software Solutions
1038
AP Medesthetics Inc./VeinGogh
3493
Aqua Pharmaceuticals
1339
Aquavit Pharmaceuticals Inc.
2381
Ascentium Capital LLC
1036
Asclepion Laser Technologies
1533
Asembia LLC
1062
Aubio Life Sciences
3386
Aurora Diagnostics
1041
AzaClear3566
Bako Integrated Physician Solutions
1128
Bank of America Practice Solutions
1264
Bayer2041
Baylor Scott & White Health
1567
Beiersdorf Inc.
2753
Beijing Sincoheren S&T Development
Co. Ltd.
3458
Beijing Syntech Laser Co. Ltd.
3074
Bellaire Industry/Mesopen
2977
Benev Co. Inc.
3075
Bio-Oil2375
MAPS
A-C
3530
2635
2079
EXPLORE THE EXHIBIT HALL
Circadia by Dr. Pugliese
2478
Clinical Resolution Lab Inc.
1867
CLN Skin Care (TopMD Skin Care)
1114
CNH Pillow Inc.
3219
Coalition of Skin Diseases
2735
Cobalt Medical Supply Inc.
1115
CoLabs International Corp.
3419
Collagen P.I.N.
1688
Compulink Business Systems Inc.
2675
Coolibar, Sun Protection You Wear
1432
Corrona LLC
1676
Cortex Technology Aps
2622
CosMedical Technologies LLC
2470
Cosmofrance Inc.
3553
CPa Medical Billing
2971
CRC Press - Taylor & Francis
1563
Crown Laboratories Inc.
2435
CryoProbe1054
Crystal Clear Digital Marketing
3508
Cu-Tech1213
CureMD Healthcare
2074
Cutanea Life Sciences Inc.
2889
Cutera2527
Cutis & Cosmetic Dermatology
1767
Cynosure1439
Cynova Laboratories
1183
D-F
D-Path Dermatopathology
3359
Daavlin3153
DANA3492
DefenAge1286
DEKA Medical
1469
Delasco1505
Demandforce Inc.
1004
Derm1012923
Derma Faith LLC
3575
Dermablend1960
DermapenWorld-Equipmed USA
2583
DermaSweep2075
Dermatologic Cosmetic Laboratories 1427
Dermatologist, The
2822
Dermatology Associates
3460
Dermatology Foundation
3310
Dermatology News
1769
Dermatology Solutions Group
1788
Dermatology Times
1527
DermLink Inc.
2581
DermOne LLC
1056
DermoScan GmbH
1377
Dermpath Diagnostics
1353
Dermpath Lab of Central States
3327
DermResources LLC
2370
DermTech2276
Dermwise3541
Designs for Vision Inc.
2078
Dino-Lite Scopes (BigC)
1575
Dow Development Laboratories
3408
Dr. Marder Skincare
3583
DRE Medical Inc.
3464
eClinicalWorks1877
Eclipse Aesthetics LLC
2875
Elekta3509
Ellipse Inc.
1023
34
Experience AAD in Orlando
Data current as of Feb. 1, 2017.
Ellis Instruments
1626
ELON Hair, Nails & Skin
3188
Elsevier3205
EltaMD SkinCare
1026, 1319
Emirates Dermatology Society
1770
Emvera Technologies LLC
1978
EndyMed Medical Ltd.
2981
Envy Medical
1219
Epionce1775
Erchonia Corp.
1953
eRelevance Corp.
1029
Espada Dermatology
1778
EunSung Global Corp.
3169
Euro-Asian Association of
Dermatovenerologists1021
European Academy of Dermatology
and Venereology
0001
Exeltis USA
3531
EZDerm LLC
1005
Feel Good Inc.
3585, 1076
Ferndale Healthcare Inc.
2319
FibroTx LLC
1170
FIGS1281
FineMec Co. Ltd.
1169
Focus Medical
2775
Forefront Dermatology
2781
Fotofinder Systems Inc.
1969
Fotona Lasers
1105
G-I
Galderma Laboratories, LP
1605
Genentech, a Member of the
Roche Group
1305
Gensco1175
GliSODin Skin Nutrients
1474
GlitterTots1180
Glowbiotics MD
2383
Gold Bond Ultimate
3475
Grand Aespio Inc.
3471
Group Health Physicians
3318
Guangzhou Huafei Tongda Technology
Co. Ltd.
1289
Haircheck3423
HairMax-Lexington International
1675
Hankins Consulting
1066
Hans Biomed USA Inc.
1078
Hansderma3518
Hayden Medical Instruments
1870
Healio Dermatology
1090
Heine USA Ltd.
3161
Henry Schein
1274
Hidrex USA
3414
Hill Dermaceuticals Inc.
1426
Hill Laboratories Co.
3427
Hill Top Research
1831
Hironic Co. Ltd.
1288
Horus-Adamo SRL
1177
HRA Healthcare Research & Analytics 1116
Hy-Tape International
1019
HydraFacial MD - Edge Systems LLC
1515
HydroPeptide2483
Iagnosis Inc./DermatologistOnCall
3363
Ibero Latin American College of
Dermatology/CILAD1689
IFC SA
1381
ILOODA Co. Ltd.
1187
Image Skincare
1275
Infinity Massage Chairs
3488
Innovaderm Research
1165
Innovative Optics Laser Eye Protection 2326
Innovative Skincare
1489
Integrated Dermatology Group 2767, 3022
Interderma, S.L.
3366
International Society of Dermatology 3313
Irmat Pharmacy
3459
ISDIN
2389, 2489
J-L
JAMA Network, The
3405
Jan Marini Skin Research
2535
Janssen Biotech, Inc.
3005
JILIN PROVINCE KING LASER
TECHNOLOGY CO. LTD.
2886
Johnson & Johnson Consumer Inc.
2805
Journal of Clinical and Aesthetic
Dermatology2565
Journey Medical Corp.
3462
JP Medical Publisher
1044
Kaiser Permanente
3035
Kao USA Inc.
3333
Karger Publishers
1205
KCD Medical
1966
Kernel Medical
1375
La Roche-Posay
1661
Laboratoires Filorga
3375
LASERING SRL
3321
Laseroptek Co. Ltd.
3481
Laservision1130
LC Cell
3287
LEO Pharma Inc.
2827, 3211
LIFTLAB Skin Regeneration
2787
Light Age Inc.
1433
LightScalpel3504
Lilly USA, LLC
3435, 3545
Lipotec USA Inc.
1013
LIPSMART1074
Locks of Love Inc.
1308
Lumenis2541
Lutronic2867
M-O
MartiDerm1060
Mastocytosis Society Inc., The
1291
Mayne Pharma
1481
Mayo Clinic
1193
McGraw-Hill Education
3291
MCV Physicians-VCU Health
1693
md:ceuticals3387
MDRejuvena Inc.
3505
MedCo Data
3368
Medesthetics Magazine
2785
Medicol USA
1032
Medimetriks Pharmaceuticals
1207
MEDWEB1366
Melanoma Foundation of NE/
Brightguard3589
Mentholatum Co., The
3515
While every effort is made to ensure the accuracy of data within this publication,
the publisher cannot be held responsible for errors or omissions.
EXPLORE THE EXHIBIT HALL
Data current as of Feb. 1, 2017.
V-Z
NOTES
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
CITY GUIDE
Valeant Pharmaceuticals North America
LLC2005
Venus Concept USA Inc.
1121
Viscot Medical LLC
2274
VisualDx3544
Vivacare1671
Viveve Inc.
3465
Viviscal Professional
1082
VivoSight1475
Vydence Medical
1031
Wallaroo Hat Co.
1569
West-TeleVox Solutions
1619
Wiley2060
Wolters Kluwer
1529
WON TECH Co. Ltd.
2883
Xoft-a subsidiary of iCAD Inc.
3413
XTETIC2975
Young Pharmaceuticals Inc.
1553
Zero Gravity
1087, 3586
Zimmer Medizin Systems
1361
ZO Skin Health Inc.
2069
Zocular3469
MAPS
Samumed LLC
3537
Sanford Health
3267
SanovaWorks (including JDD)
3320
SanSoleil...Sun Care You Can Wear...
1593
Sawgio LLC
2880
Scar Heal
2174
Schweiger Dermatology Group
3523
SciBase1120
Sciton1819
SCS Direct Inc.
3513
Sebamed USA
3286
Sebela Pharmaceuticals Inc.
3365
Sensus Healthcare
2275
Sente3567
Sesderma1313
SESHA Skin Therapy
3410
Shantel Medical Supply
2623
SharpLight Technologies Ltd.
3314
Shenzhen GSD Tech Co. Ltd.
1278
SILAB3486
Sinclair Pharma
2989
Skin1017
Skin & Cancer Associates/
Advanced Dermatology Mgmt
2963
Skin Cancer Foundation, The
3221
Skin Disease Education Foundation
1771
SkinCeuticals1653
SkinGen International Inc.
1020
SmartPractice2823
Society of Dermatology Physician
Assistants3315
Solumbra by Sun Precautions
3353
Solutionreach3528
Sterilis LLC
3571
EXHIBIT HALL
Palmer’s2969
PatientPoint1014
Payspan Inc.
1084
PCA Skin
1253
Peninsula Medical
3191
PerfAction Technologies
3089
Perigee1581
Perimed Inc.
2379
Perrigo3264
Person & Covey
1668
Pfizer Inc.
2589
Philips Respironics
3533
S-U
Stiefel, a GSK company
1389
STRATA Skin Sciences
2035
StrataDx1961
Stratpharma Switzerland
1182
Sun Pharma
3127
Sun Products
2741
Sun Protection Zone
3031
Suneva Medical
1667
SurgiTel/General Scientific Corp.
2271
Swiss-American Mfg. & Product
Development2834
Symbio LLC
3406
Syneron Candela
2953
Syris Scientific
3404
taberna pro medicum
2227
Tender Corp.
1293
Teoxane Laboratories
1088
Tergus Pharma LLC
3564
Theradome Inc.
3557
Thermi3081
ThermoTek Inc.
2175
Tiemann-Bernsco2405
Tilley Endurables
2922
Tizo by Fallene Ltd.
1719
TKL Research
1065
Topix Pharmaceuticals Inc.
2019
Total Clinical Trial Management
3590
Ultralite Enterprises Inc.
2530
Under Skin
2722
Unilever2835
United Skin Specialists
3487
Unity Point Health-Methodist Proctor 1589
University of Florida Health
Pathology Laboratorie
3489
UV Skinz Inc.
3369
UVBIOTEK1591
EDUCATION
P-R
PhotoMedex2135
PhytoCeuticals Inc.
3163
Pierre Fabre USA
3041
Practical Dermatology
3062
Precision Medical Devices LLC
1287
PRIME Journal
1030
ProCell Therapies
3570
Procter & Gamble
2231
Proinnovera GmbH
1091
Promius Pharma
1461
Promoitalia Group S.P.A.
1386
ProPath Dermatopathology
2027
PSI/Vanicream Skin Care
2127
Psoria-Shield Inc.
1068
Quanta USA
3063
Quantificare2474
Quintessence Skin Science
3130
Ra Medical Systems Inc.
2567
Refine USA
2482
Regen Lab
3407
Regeneron/Sanofi Genzyme
3175
RegimenMD LLC
1266
Restoration Robotics
3239
Revision Skincare
1241
Riverchase Dermatology
3591
Robbins Instruments
1304
Rohrer Aesthetics LLC
2791
Rose Micro Solutions 1126, 1930, 2064, 3445
WELCOME
Mercedes Medical
3269
Merz3015
Mesoestetic SL
2680
MetaOptima Technology Inc.
2684
Microsurgery Instruments Inc.
2536
Midmark Corp.
2727
Miraca Life Sciences
2575
Miramar Labs Inc.
1035
Mission Pharmacal Co.
1975
MJD Patient Comm/TopDocs.com
2523
Modernizing Medicine Inc.
2665
MoleSafe1774
MolluscumRx.1006
Mother To Baby Pregnancy Studies
conducted by OTIS
1329
MTI Inc.
3343
Mylan Inc.
3563
Myriad Genetic Laboratories Inc.
1052
Nanbu Plastics Co. Ltd.
1282
National Biological Corp.
2453
Nelly De Vuyst Derme & Co.
3261
NeoGraft3520
NeoStrata Co. Inc.
1539
Neutrogena2505
New Beauty Magazine
1331
New Medical Technology Inc.
1974
NEWPONG CO. Ltd.
3581
NewSurg1008
Nextech2417
NextGen Healthcare
3519
NIA241290
NIAMS2327
NoIR LaserShields
1327
NovaCutis Inc.
1577
Novartis Pharmaceuticals
Corp.
1627, 1635, 1937
Novella Clinical
1367
Novoxel Ltd.
1080
Nutrafol1012
NY LASER OUTLET
1016
Oculo-Plastik Inc.
1118
OCuSOFTSkin Care
3260
Officite1674
Omni Bioceutical Innovations
3381
Omnilux3559
Ontos Inc.
1011
Otto Trading Inc.
1027, 1270
Outcome Health
1075
Oxygenetix Institute Inc.
1875
aad.org 35
BOTOX® Cosmetic (onabotulinumtoxinA) IMPORTANT SAFETY
INFORMATION (continued)
CONTRAINDICATIONS
BOTOX® Cosmetic is contraindicated in the presence of infection at the
proposed injection site(s) and in individuals with known hypersensitivity
to any botulinum toxin preparation or to any of the components in
the formulation.
WARNINGS AND PRECAUTIONS
Lack of Interchangeability between Botulinum Toxin Products
The potency Units of BOTOX® Cosmetic are specific to
the preparation and assay method utilized. They are not
interchangeable with other preparations of botulinum toxin
products and, therefore, units of biological activity of
BOTOX® Cosmetic cannot be compared to nor converted into
units of any other botulinum toxin products assessed with any
other specific assay method.
Spread of Toxin Effect
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
No definitive serious adverse event reports of distant spread of toxin effect
associated with dermatologic use of BOTOX® Cosmetic at the labeled
dose of 20 Units (for glabellar lines), 24 Units (for lateral canthal lines),
44 Units (for simultaneous treatment of lateral canthal lines and glabellar
lines) have been reported.
Serious Adverse Reactions With Unapproved Use
Serious adverse reactions, including excessive weakness, dysphagia,
and aspiration pneumonia, with some adverse reactions associated with
fatal outcomes, have been reported in patients who received BOTOX®
injections for unapproved uses. In these cases, the adverse reactions
were not necessarily related to distant spread of toxin, but may have
resulted from the administration of BOTOX® to the site of injection and/
or adjacent structures. In several of the cases, patients had pre-existing
dysphagia or other significant disabilities. There is insufficient information
to identify factors associated with an increased risk for adverse reactions
associated with the unapproved uses of BOTOX®. The safety and
effectiveness of BOTOX® for unapproved uses have not been established.
Hypersensitivity Reactions
Serious and/or immediate hypersensitivity reactions have been reported.
These reactions include anaphylaxis, serum sickness, urticaria, soft-tissue
edema, and dyspnea. If such reactions occur, further injection of
BOTOX® Cosmetic should be discontinued and appropriate medical
therapy immediately instituted. One fatal case of anaphylaxis has been
reported in which lidocaine was used as the diluent and, consequently,
the causal agent cannot be reliably determined.
Cardiovascular System
There have been reports following administration of BOTOX® of adverse
events involving the cardiovascular system, including arrhythmia and
myocardial infarction, some with fatal outcomes. Some of these patients
had risk factors including pre-existing cardiovascular disease. Use caution
when administering to patients with pre-existing cardiovascular disease.
Pre-existing Neuromuscular Disorders
Individuals with peripheral motor neuropathic diseases, amyotrophic
lateral sclerosis, or neuromuscular junction disorders (eg, myasthenia
gravis or Lambert-Eaton syndrome) should be monitored when given
botulinum toxin. Patients with neuromuscular disorders may be at
increased risk of clinically significant effects including generalized muscle
weakness, diplopia, ptosis, dysphonia, dysarthria, severe dysphagia,
and respiratory compromise from onabotulinumtoxinA (see Warnings
and Precautions).
Dysphagia and Breathing Difficulties
Treatment with BOTOX® and other botulinum toxin products can
result in swallowing or breathing difficulties. Patients with pre-existing
swallowing or breathing difficulties may be more susceptible to these
complications. In most cases, this is a consequence of weakening
of muscles in the area of injection that are involved in breathing or
oropharyngeal muscles that control swallowing or breathing (see
Boxed Warning).
Pre-existing Conditions at the Injection Site
Caution should be used when BOTOX® Cosmetic treatment is used in
the presence of inflammation at the proposed injection site(s) or when
excessive weakness or atrophy is present in the target muscle(s).
Human Albumin and Transmission of Viral Diseases
This product contains albumin, a derivative of human blood. Based on
effective donor screening and product manufacturing processes, it carries
an extremely remote risk for transmission of viral diseases. A theoretical
risk for transmission of Creutzfeldt-Jakob disease (CJD) also is considered
extremely remote. No cases of transmission of viral diseases or CJD have
ever been identified for albumin.
ADVERSE REACTIONS
The most frequently reported adverse event following injection of
BOTOX® Cosmetic for glabellar lines was eyelid ptosis (3%).
The most frequently reported adverse event following injection
of BOTOX® Cosmetic for lateral canthal lines was eyelid edema (1%).
DRUG INTERACTIONS
Co-administration of BOTOX® Cosmetic and aminoglycosides or
other agents interfering with neuromuscular transmission (eg, curarelike compounds) should only be performed with caution as the
effect of the toxin may be potentiated. Use of anticholinergic drugs
after administration of BOTOX® Cosmetic may potentiate systemic
anticholinergic effects.
The effect of administering different botulinum neurotoxin products
at the same time or within several months of each other is unknown.
Excessive neuromuscular weakness may be exacerbated by
administration of another botulinum toxin prior to the resolution of
the effects of a previously administered
botulinum toxin.
Excessive weakness may also be exaggerated by administration of a
muscle relaxant before or after administration of BOTOX® Cosmetic.
USE IN SPECIFIC POPULATIONS
BOTOX® Cosmetic is not recommended for use in children or pregnant
women. It is not known whether BOTOX® Cosmetic is excreted in
human milk. Caution should be exercised when BOTOX® Cosmetic is
administered to a nursing woman.
Please see brief summary of full Prescribing
Information on the following pages.
Actual patient treated for moderate
to severe crow’s feet and glabellar lines.
Results may vary.
© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners.
BotoxCosmetic.com 1-800-BOTOXMD BCT103413 11/16
He knows
the name,
you know
the results
Men are ready
for you to start
the conversation
Indications
Glabellar Lines
BOTOX® Cosmetic (onabotulinumtoxinA) for injection is indicated for the
temporary improvement in the appearance of moderate to severe glabellar lines
associated with corrugator and/or procerus muscle activity in adult patients.
Lateral Canthal Lines
BOTOX® Cosmetic is indicated for the temporary improvement in the
appearance of moderate to severe lateral canthal lines associated with
orbicularis oculi activity in adult patients.
IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports indicate that the effects of BOTOX® Cosmetic and all botulinum toxin products may spread from the area of injection to produce
symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia,
dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and
breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for
spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying
condition that would predispose them to these symptoms. In unapproved uses, including spasticity in children, and in approved indications, cases of
spread of effect have been reported at doses comparable to those used to treat cervical dystonia and upper limb spasticity and at lower doses.
Please see additional Important Safety Information about BOTOX® Cosmetic on opposite page.
EXPLORE THE EXHIBIT HALL
Data current as of Feb. 1, 2017.
Exhibitors
BY BOOTH NUMBER
0s
0001 European Academy of Dermatology
and Venereology
1000s
1004 Demandforce Inc.
1005 EZDerm LLC
1006MolluscumRx.
1008NewSurg
1011 Ontos Inc.
1012Nutrafol
1013 Lipotec USA Inc.
1014PatientPoint
1016 NY LASER OUTLET
1017Skin
1019 Hy-Tape International
1020 SkinGen International Inc.
1021 Euro-Asian Association of
Dermatovenerologists
1023 Ellipse Inc.
1026 EltaMD SkinCare
1027 Otto Trading Inc.
1029 eRelevance Corp.
1030 PRIME Journal
1031 Vydence Medical
1032 Medicol USA
1035 Miramar Labs Inc.
1036 Ascentium Capital LLC
1038 AP Easy Software Solutions
1040 Biologica Technologies
1041 Aurora Diagnostics
1044 JP Medical Publisher
38
Experience AAD in Orlando
1052 Myriad Genetic Laboratories Inc.
1053 Celgene Corp.
1054CryoProbe
1056 DermOne LLC
1058 Advanced Rad Solutions
1060MartiDerm
1062 Asembia LLC
1064 Centura Pharmaceuticals Inc.
1065 TKL Research
1066 Hankins Consulting
1068 Psoria-Shield Inc.
1070AccuVein
1071 Carismed GmbH
1074LIPSMART
1075 Outcome Health
1076 Feel Good Inc.
1078 Hans Biomed USA Inc.
1080 Novoxel Ltd.
1081 AnteAGE MD by Cellese
1082 Viviscal Professional
1084 Payspan Inc.
1087 Zero Gravity
1088 Teoxane Laboratories
1090 Healio Dermatology
1091 Proinnovera GmbH
1105 Fotona Lasers
1110 Castle Biosciences Inc.
1114 CLN Skin Care (TopMD Skin Care)
1115 Cobalt Medical Supply Inc.
1116 HRA Healthcare Research & Analytics
1118 Oculo-Plastik Inc.
1120SciBase
1121 Venus Concept USA Inc.
1126 Rose Micro Solutions
1127CareCredit
1128 Bako Integrated Physician Solutions
1130Laservision
1133BTL
1165 Innovaderm Research
1169 FineMec Co. Ltd.
1170 FibroTx LLC
1175Gensco
1177 Horus-Adamo SRL
1180GlitterTots
1182 Stratpharma Switzerland
1183 Cynova Laboratories
1186 Biogenix Skin Sciences
1187 ILOODA Co. Ltd.
1193 Mayo Clinic
1205 Karger Publishers
1207 Medimetriks Pharmaceuticals
1213Cu-Tech
1219 Envy Medical
1241 Revision Skincare
1253 PCA Skin
1261 bioskin GmbH
1264 Bank of America Practice Solutions
1265 Agnes formerly Gowoonsesang
Cosmetics
1266 RegimenMD LLC
1270 Otto Trading Inc.
1274 Henry Schein
1275 Image Skincare
1278 Shenzhen GSD Tech Co. Ltd.
While every effort is made to ensure the accuracy of data within this publication,
the publisher cannot be held responsible for errors or omissions.
EXPLORE THE EXHIBIT HALL
Data current
of of
Feb.
1, 2017.
Data
currentasas
Feb.
1, 2017.
NOTES
aad.org 39
CITY GUIDE
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
MAPS
2005 Valeant Pharmaceuticals North America
LLC
2019 Topix Pharmaceuticals Inc.
2027 ProPath Dermatopathology
2035 STRATA Skin Sciences
2041Bayer
2053AbbVie
2060Wiley
2064 Rose Micro Solutions
2069 ZO Skin Health Inc.
EXHIBIT HALL
2000s
2074 CureMD Healthcare
2075DermaSweep
2078 Designs for Vision Inc.
2079 5CC (5-Continent-Congress)
2127 PSI/Vanicream Skin Care
2135PhotoMedex
2174 Scar Heal
2175 ThermoTek Inc.
2177 Advanced MD Inc.
2178Accredo
2219Acuderm
2226 Brymill Cryogenic Systems
2227 taberna pro medicum
2231 Procter & Gamble
2253Allergan
2271 SurgiTel/General Scientific Corp.
2274 Viscot Medical LLC
2275 Sensus Healthcare
2276DermTech
2319 Ferndale Healthcare Inc.
2326 Innovative Optics Laser Eye Protection
2327NIAMS
2370 DermResources LLC
2371 Bovie Medical
2375Bio-Oil
2379 Perimed Inc.
2381 Aquavit Pharmaceuticals Inc.
2383 Glowbiotics MD
2389ISDIN
2405Tiemann-Bernsco
2417Nextech
2426 American Society for Dermatologic
Surgery
2431Biodermis
2435 Crown Laboratories Inc.
2441AbbVie
2453 National Biological Corp.
2461 Alma Lasers
2470 CosMedical Technologies LLC
2474Quantificare
2475 Brazilian Society for Dermatological
Surgery
2478 Circadia by Dr. Pugliese
2482 Refine USA
2483HydroPeptide
2489ISDIN
2505Neutrogena
2523 MJD Patient Comm/TopDocs.com
2527Cutera
2530 Ultralite Enterprises Inc.
2535 Jan Marini Skin Research
2536 Microsurgery Instruments Inc.
2541Lumenis
2553 Amgen Inc.
2565 Journal of Clinical and Aesthetic
Dermatology
2567 Ra Medical Systems Inc.
2575 Miraca Life Sciences
2581 DermLink Inc.
2583 DermapenWorld-Equipmed USA
2589 Pfizer Inc.
2622 Cortex Technology Aps
2623 Shantel Medical Supply
2635 3Gen Inc./DermLite
EDUCATION
1627 Novartis Pharmaceuticals Corp.
1635 Novartis Pharmaceuticals Corp.
1653SkinCeuticals
1661 La Roche-Posay
1662 Chemotechnique Diagnostics/Dormer
Laboratories
1666 Alphaeon Corp.
1667 Suneva Medical
1668 Person & Covey
1671Vivacare
1674Officite
1675 HairMax-Lexington International
1676 Corrona LLC
1679Advalight
1683 Cipher Pharmaceuticals Inc.
1688 Collagen P.I.N.
1689 Ibero Latin American College of
Dermatology/CILAD
1691Bloq-UV
1692 AD Surgical
1693 MCV Physicians-VCU Health
1719 Tizo by Fallene Ltd.
1766 Action Bag Co.
1767 Cutis & Cosmetic Dermatology
1768 CarePath Diagnostics
1769 Dermatology News
1770 Emirates Dermatology Society
1771 Skin Disease Education Foundation
1774MoleSafe
1775Epionce
1778 Espada Dermatology
1788 Dermatology Solutions Group
1819Sciton
1831 Hill Top Research
1866 Caliber Imaging & Diagnostics
1867 Clinical Resolution Lab Inc.
1870 Hayden Medical Instruments
1875 Oxygenetix Institute Inc.
1877eClinicalWorks
1919 Biopelle Inc.
1927 Canfield Scientific
1930 Rose Micro Solutions
1937 Novartis Pharmaceuticals Corp.
1953 Erchonia Corp.
1960Dermablend
1961StrataDx
1965 AccuTEC Blades
1966 KCD Medical
1969 Fotofinder Systems Inc.
1974 New Medical Technology Inc.
1975 Mission Pharmacal Co.
1978 Emvera Technologies LLC
WELCOME
1281FIGS
1282 Nanbu Plastics Co. Ltd.
1286DefenAge
1287 Precision Medical Devices LLC
1288 Hironic Co. Ltd.
1289 Guangzhou Huafei Tongda Technology
Co. Ltd.
1290NIA24
1291 Mastocytosis Society Inc., The
1293 Tender Corp.
1304 Robbins Instruments
1305 Genentech, a Member of the Roche
Group
1308 Locks of Love Inc.
1313Sesderma
1319 EltaMD SkinCare
1327 NoIR LaserShields
1329 Mother To Baby Pregnancy Studies
conducted by OTIS
1331 New Beauty Magazine
1335 Aesthetic Guide, The
1339 Aqua Pharmaceuticals
1353 Dermpath Diagnostics
1360 Advanced Skin & Hair
1361 Zimmer Medizin Systems
1366MEDWEB
1367 Novella Clinical
1375 Kernel Medical
1377 DermoScan GmbH
1381 IFC SA
1386 Promoitalia Group S.P.A.
1389 Stiefel, a GSK company
1390 Bios SRL
1426 Hill Dermaceuticals Inc.
1427 Dermatologic Cosmetic Laboratories
1432 Coolibar, Sun Protection You Wear
1433 Light Age Inc.
1439Cynosure
1461 Promius Pharma
1469 DEKA Medical
1474 GliSODin Skin Nutrients
1475VivoSight
1481 Mayne Pharma
1489 Innovative Skincare
1505Delasco
1515 HydraFacial MD - Edge Systems LLC
1521Aerolase
1527 Dermatology Times
1529 Wolters Kluwer
1533 Asclepion Laser Technologies
1539 NeoStrata Co. Inc.
1553 Young Pharmaceuticals Inc.
1563 CRC Press - Taylor & Francis
1567 Baylor Scott & White Health
1569 Wallaroo Hat Co.
1575 Dino-Lite Scopes (BigC)
1577 NovaCutis Inc.
1581Perigee
1589 Unity Point Health-Methodist Proctor
1591UVBIOTEK
1593 SanSoleil...Sun Care You Can Wear...
1605 Galderma Laboratories, LP
1619 West-TeleVox Solutions
1626 Ellis Instruments
EXPLORE THE EXHIBIT HALL
2664 Actelion Pharmaceuticals US
2665 Modernizing Medicine Inc.
2675 Compulink Business Systems Inc.
2680 Mesoestetic SL
2683 Capillus LLC
2684 MetaOptima Technology Inc.
2722 Under Skin
2723 American Society for Mohs Surgery
2727 Midmark Corp.
2735 Coalition of Skin Diseases
2741 Sun Products
2753 Beiersdorf Inc.
2767 Integrated Dermatology Group
2775 Focus Medical
2781 Forefront Dermatology
2785 Medesthetics Magazine
2787 LIFTLAB Skin Regeneration
2791 Rohrer Aesthetics LLC
2805 Johnson & Johnson Consumer Inc.
2822 Dermatologist, The
2823SmartPractice
2827 LEO Pharma Inc.
2834 Swiss-American Mfg. & Product
Development
2835Unilever
2867Lutronic
2875 Eclipse Aesthetics LLC
2880 Sawgio LLC
2883 WON TECH Co. Ltd.
2884 Chemistry Rx
2886 JILIN PROVINCE KING LASER
TECHNOLOGY CO. LTD.
2889 Cutanea Life Sciences Inc.
2922 Tilley Endurables
2923Derm101
2953 Syneron Candela
2963 Skin & Cancer Associates/Advanced
Dermatology Mgmt
2969Palmer’s
2971 CPa Medical Billing
2975XTETIC
2977 Bellaire Industry/Mesopen
2981 EndyMed Medical Ltd.
2989 Sinclair Pharma
3000s
3005 Janssen Biotech, Inc.
3015Merz
3022 Integrated Dermatology Group
3031 Sun Protection Zone
3035 Kaiser Permanente
3041 Pierre Fabre USA
3062 Practical Dermatology
3063 Quanta USA
3074 Beijing Syntech Laser Co. Ltd.
3075 Benev Co. Inc.
3081Thermi
3089 PerfAction Technologies
3127 Sun Pharma
3130 Quintessence Skin Science
3134 American Board of Dermatology
3153Daavlin
3161 Heine USA Ltd.
3163 PhytoCeuticals Inc.
3169 EunSung Global Corp.
40
Experience AAD in Orlando
Data current as of Feb. 1, 2017.
3175 Regeneron/Sanofi Genzyme
3187 Adako USA
3188 ELON Hair, Nails & Skin
3191 Peninsula Medical
3192 Advanced Technology Laser Co. Ltd.
3205Elsevier
3211 LEO Pharma Inc.
3215 Advanced Dermatology & Cosmetic
Surgery
3219 CNH Pillow Inc.
3221 Skin Cancer Foundation, The
3239 Restoration Robotics
3260 OCuSOFTSkin Care
3261 Nelly De Vuyst Derme & Co.
3264Perrigo
3267 Sanford Health
3269 Mercedes Medical
3271 Accurate Manufacturing Inc.
3286 Sebamed USA
3287 LC Cell
3291 McGraw-Hill Education
3293Biodermis
3305 Anthony Products/Gio Pelle
3310 Dermatology Foundation
3313 International Society of Dermatology
3314 SharpLight Technologies Ltd.
3315 Society of Dermatology Physician
Assistants
3318 Group Health Physicians
3320 SanovaWorks (including JDD)
3321 LASERING SRL
3327 Dermpath Lab of Central States
3333 Kao USA Inc.
3343 MTI Inc.
3353 Solumbra by Sun Precautions
3359 D-Path Dermatopathology
3363 Iagnosis Inc./DermatologistOnCall
3365 Sebela Pharmaceuticals Inc.
3366 Interderma, S.L.
3368 MedCo Data
3369 UV Skinz Inc.
3375 Laboratoires Filorga
3381 Omni Bioceutical Innovations
3386 Aubio Life Sciences
3387md:ceuticals
3388 Biomed Diagnostics
3389 Allied Powers LLC
3390BioPharmX
3391 Anne Arundel Dermatology, P.A.
3404 Syris Scientific
3405 JAMA Network, The
3406 Symbio LLC
3407 Regen Lab
3408 Dow Development Laboratories
3410 SESHA Skin Therapy
3412 AMP Medical Products LLC
3413 Xoft-a subsidiary of iCAD Inc.
3414 Hidrex USA
3416 Blaine Labs Inc.
3419 CoLabs International Corp.
3423Haircheck
3427 Hill Laboratories Co.
3435 Lilly USA, LLC
3445 Rose Micro Solutions
3453 brandMD Skin Care
3458 Beijing Sincoheren S&T Development
Co. Ltd.
3459 Irmat Pharmacy
3460 Dermatology Associates
3462 Journey Medical Corp.
3464 DRE Medical Inc.
3465 Viveve Inc.
3469Zocular
3471 Grand Aespio Inc.
3475 Gold Bond Ultimate
3481 Laseroptek Co. Ltd.
3486SILAB
3487 United Skin Specialists
3488 Infinity Massage Chairs
3489 University of Florida Health Pathology
Laboratorie
3491 American College of Phlebology
3492DANA
3493 AP Medesthetics Inc./VeinGogh
3504LightScalpel
3505 MDRejuvena Inc.
3508 Crystal Clear Digital Marketing
3509Elekta
3513 SCS Direct Inc.
3515 Mentholatum Co., The
3518Hansderma
3519 NextGen Healthcare
3520NeoGraft
3523 Schweiger Dermatology Group
3526 Aclaris Therapeutics Inc.
3527 Boehringer Ingelheim Pharmaceuticals
Inc.
3528Solutionreach
3530 21st Century Oncology
3531 Exeltis USA
3533 Philips Respironics
3537 Samumed LLC
3541Dermwise
3543 Cabana Life
3544VisualDx
3545 Lilly USA, LLC
3553 Cosmofrance Inc.
3557 Theradome Inc.
3558 Anutra Medical
3559Omnilux
3563 Mylan Inc.
3564 Tergus Pharma LLC
3566AzaClear
3567Sente
3570 ProCell Therapies
3571 Sterilis LLC
3575 Derma Faith LLC
3579 Biofrontera Inc.
3581 NEWPONG CO. Ltd.
3583 Dr. Marder Skincare
3585 Feel Good Inc.
3586 Zero Gravity
3588 Allina Health
3589 Melanoma Foundation of NE/
Brightguard
3590 Total Clinical Trial Management
3591 Riverchase Dermatology
While every effort is made to ensure the accuracy of data within this publication,
the publisher cannot be held responsible for errors or omissions.
BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION
Neuromuscular Blocking Agents
This Brief Summary does not include all the information needed to use ONEXTON
Gel safely and effectively. See full prescribing information for ONEXTON Gel.
Clindamycin has been shown to have neuromuscular blocking properties that may
enhance the action of other neuromuscular blocking agents. ONEXTON Gel should be
used with caution in patients receiving such agents.
ONEXTON™ (clindamycin phosphate and benzoyl peroxide) Gel, 1.2%/3.75%, for
topical use
Initial U.S. Approval: 2000
CONTRAINDICATIONS
Hypersensitivity
ONEXTON Gel is contraindicated in those individuals who have shown hypersensitivity
to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin.
Anaphylaxis, as well as allergic reactions leading to hospitalization, has been reported
in postmarketing use with ONEXTON Gel [see Adverse Reactions]
WARNINGS AND PRECAUTIONS
Colitis/Enteritis
Systemic absorption of clindamycin has been demonstrated following topical use of
clindamycin. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous
colitis) have been reported with the use of topical and systemic clindamycin. If
significant diarrhea occurs, ONEXTON Gel should be discontinued.
Severe colitis has occurred following oral and parenteral administration of
clindamycin with an onset of up to several weeks following cessation of therapy.
Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong
and/or worsen severe colitis. Severe colitis may result in death.
Studies indicate toxin(s) produced by Clostridia is one primary cause of antibiotic-associated
colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal
cramps and may be associated with the passage of blood and mucus. Stool cultures for
Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.
Ultraviolet Light and Environmental Exposure
Minimize sun exposure (including use of tanning beds or sun lamps) following drug
application [see Nonclinical Toxicology].
ADVERSE REACTIONS
The following adverse reaction is described in more detail in the Warnings and
Precautions section of the label:
Colitis [see Warnings and Precautions].
Table 1: Local Skin Reactions - Percent of Subjects with Symptoms Present.
Results from the Phase 3 Trial of ONEXTON Gel 1.2%/3.75% (N = 243)
Before Treatment
(Baseline)
Maximum During
Treatment
End of Treatment
(Week 12)
Mild Mod.* Severe
Mild Mod.* Severe
Mild Mod.* Severe
Erythema
20
6
0
28
5
<1
15
2
0
Scaling
10
1
0
19
3
0
10
<1
0
Itching
14
3
<1
15
3
0
7
2
0
Burning
5
<1
<1
7
1
<1
3
<1
0
Stinging
5
<1
0
7
0
<1
3
0
<1
*Mod. = Moderate
Postmarketing Experience
Because postmarketing adverse reactions are reported voluntarily from a population
of uncertain size, it is not always possible to reliably estimate their frequency or
establish a causal relationship to drug exposure.
Anaphylaxis, as well as allergic reactions leading to hospitalizations, has been reported
in postmarketing use of products containing clindamycin phosphate/benzoyl peroxide.
DRUG INTERACTIONS
Erythromycin
Avoid using ONEXTON Gel in combination with topical or oral erythromycincontaining products due to its clindamycin component. In vitro studies have shown
antagonism between erythromycin and clindamycin. The clinical significance of this in
vitro antagonism is not known.
Concomitant Topical Medications
Concomitant topical acne therapy should be used with caution since a possible
cumulative irritancy effect may occur, especially with the use of peeling, desquamating,
or abrasive agents. If irritancy or dermatitis occurs, reduce frequency of application
or temporarily interrupt treatment and resume once the irritation subsides. Treatment
should be discontinued if the irritation persists.
Nursing Mothers
It is not known whether clindamycin is excreted in human milk after topical application
of ONEXTON Gel. However, orally and parenterally administered clindamycin has been
reported to appear in breast milk. Because of the potential for serious adverse reactions
in nursing infants, a decision should be made whether to use ONEXTON Gel while
nursing, taking into account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness of ONEXTON Gel in pediatric patients under the age of 12
have not been evaluated.
Geriatric Use
Clinical trials of ONEXTON Gel did not include sufficient numbers of subjects aged 65
and older to determine whether they respond differently from younger subjects.
NONCLINICAL TOXICOLOGY
Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity, mutagenicity and impairment of fertility testing of ONEXTON Gel have
not been performed.
Benzoyl peroxide has been shown to be a tumor promoter and progression agent in
a number of animal studies. Benzoyl peroxide in acetone at doses of 5 and 10 mg
administered topically twice per week for 20 weeks induced skin tumors in transgenic
Tg.AC mice. The clinical significance of this is unknown.
Carcinogenicity studies have been conducted with a gel formulation containing
1% clindamycin and 5% benzoyl peroxide. In a 2-year dermal carcinogenicity study in
mice, treatment with the gel formulation at doses of 900, 2700, and 15000 mg/kg/day
(1.8, 5.4, and 30 times amount of clindamycin and 2.4, 7.2, and 40 times amount of
benzoyl peroxide in the highest recommended adult human dose of 2.5 g ONEXTON Gel
based on mg/m2, respectively) did not cause any increase in tumors. However, topical
treatment with a different gel formulation containing 1% clindamycin and 5% benzoyl
peroxide at doses of 100, 500, and 2000 mg/kg/day caused a dose-dependent increase in
the incidence of keratoacanthoma at the treated skin site of male rats in a 2-year dermal
carcinogenicity study in rats. In an oral (gavage) carcinogenicity study in rats, treatment
with the gel formulation at doses of 300, 900 and 3000 mg/kg/day (1.2, 3.6, and 12
times amount of clindamycin and 1.6, 4.8, and 16 times amount of benzoyl peroxide
in the highest recommended adult human dose of 2.5 g ONEXTON Gel based on mg/
m2, respectively) for up to 97 weeks did not cause any increase in tumors. In a 52-week
dermal photocarcinogenicity study in hairless mice, (40 weeks of treatment followed by
12 weeks of observation), the median time to onset of skin tumor formation decreased
and the number of tumors per mouse increased relative to controls following chronic
concurrent topical administration of the higher concentration benzoyl peroxide formulation
(5000 and 10000 mg/kg/day, 5 days/week) and exposure to ultraviolet radiation.
Clindamycin phosphate was not genotoxic in the human lymphocyte chromosome
aberration assay. Benzoyl peroxide has been found to cause DNA strand breaks in a variety
of mammalian cell types, to be mutagenic in S. typhimurium tests by some but not all
investigators, and to cause sister chromatid exchanges in Chinese hamster ovary cells.
Fertility studies have not been performed with ONEXTON Gel or benzoyl peroxide,
but fertility and mating ability have been studied with clindamycin. Fertility studies in
rats treated orally with up to 300 mg/kg/day of clindamycin (approximately 120 times
the amount of clindamycin in the highest recommended adult human dose of 2.5 g
ONEXTON Gel, based on mg/m2) revealed no effects on fertility or mating ability.
PATIENT COUNSELING INFORMATION
See FDA-approved patient labeling (Patient Information).
Distributed by:
Valeant Pharmaceuticals North America LLC, Bridgewater, NJ 08807
Manufactured by:
Contract Pharmaceuticals Limited Mississauga, Ontario, Canada L5N 6L6
U.S. Patents 5,733,886 and 8,288,434
Issued 11/2014
9389300
DM/ONX/14/0031(1)
T:10.75”
S:9.75”
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction
rates observed in clinical trials of a drug cannot be directly compared to rates observed in
the clinical trials of another drug and may not reflect the rates observed in clinical practice.
These adverse reactions occurred in less than 0.5% of subjects treated with ONEXTON
Gel: burning sensation (0.4%); contact dermatitis (0.4%); pruritus (0.4%); and rash (0.4%).
During the clinical trial, subjects were assessed for local cutaneous signs and
symptoms of erythema, scaling, itching, burning and stinging. Most local skin reactions
either were the same as baseline or increased and peaked around week 4 and were
near or improved from baseline levels by week 12. The percentage of subjects that had
symptoms present before treatment (at baseline), during treatment, and the percent
with symptoms present at week 12 are shown in Table 1.
USE IN SPECIFIC POPULATIONS
Pregnancy
Pregnancy Category C.
There are no adequate and well-controlled studies in pregnant women treated with
ONEXTON Gel. ONEXTON Gel should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus.
Animal reproductive/developmental toxicity studies have not been conducted with
ONEXTON Gel or benzoyl peroxide. Developmental toxicity studies of clindamycin
performed in rats and mice using oral doses of up to 600 mg/kg/day (240 and 120
times amount of clindamycin in the highest recommended adult human dose based
on mg/m2, respectively) or subcutaneous doses of up to 200 mg/kg/day (80 and 40
times the amount of clindamycin in the highest recommended adult human dose
based on mg/m2, respectively) revealed no evidence of teratogenicity.
EXPLORE THE EXHIBIT HALL
Data current as of Feb. 1, 2017.
WELCOME
Exhibitors
BY CATEGORY
COMPUTER SOFTWARE
& HARDWARE
1038
1866
1927
2675
1004
2581
3368
1032
2523
2665
2275
AccuTEC Blades
1965
Acuderm2219
AD Surgical
1692
Chemotechnique Diagnostics/
Dormer Laboratories
1662
Cobalt Medical Supply Inc.
1115
Delasco1505
Henry Schein
1274
Laboratoires Filorga
3375
Mercedes Medical
3269
Robbins Instruments
1304
Sinclair Pharma
2989
Viscot Medical LLC
2274
EMR/EHR SYSTEMS
Advanced MD Inc.
Compulink Business Systems Inc.
CureMD Healthcare
DermLink Inc.
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
2177
2675
2074
2581
aad.org 43
NOTES
AP Easy Software Solutions
Caliber Imaging & Diagnostics
Canfield Scientific
Compulink Business Systems Inc.
Demandforce Inc.
DermLink Inc.
MedCo Data
Medicol USA
MJD Patient Comm/TopDocs.com
Modernizing Medicine Inc.
Sensus Healthcare
DISPOSABLE MEDICAL SUPPLIES
CITY GUIDE
Bloq-UV1691
Cabana Life
3543
Coolibar, Sun Protection You Wear
1432
Delasco1505
Henry Schein
1274
SanSoleil...Sun Care You Can Wear...
1593
Solumbra by Sun Precautions
3353
Tilley Endurables
2922
UV Skinz Inc.
3369
Wallaroo Hat Co.
1569
Accurate Mfg. Inc.
3271
Advanced Skin & Hair
1360
Allergan2253
Aquavit Pharmaceuticals Inc.
2381
Beiersdorf Inc.
2753
Beijing Sincoheren S&T Development
Co. Ltd.
3458
Benev Co. Inc.
3075
Bio-Oil2375
Biodermis
2431, 3293
Biopelle Inc.
1919
Bios SRL
1390
bioskin GmbH
1261
brandMD Skin Care
3453
Circadia by Dr. Pugliese
2478
Clinical Resolution Lab Inc.
1867
CLN Skin Care (TopMD Skin Care)
1114
CoLabs International Corp.
3419
CosMedical Technologies LLC
2470
Cu-Tech1213
Delasco1505
DermaSweep2075
Dermatologic Cosmetic Laboratories
1427
ELON Hair, Nails & Skin
3188
EltaMD SkinCare
1026, 1319
Envy Medical
1219
Epionce1775
Ferndale Healthcare Inc.
2319
Galderma Laboratories, LP
1605
GliSODin Skin Nutrients
1474
Glowbiotics MD
2383
Gold Bond Ultimate
3475
HydraFacial MD - Edge Systems LLC
1515
ILOODA Co. Ltd.
1187
Image Skincare
1275
Innovaderm Research
1165
Innovative Skincare
1489
Interderma, S.L.
3366
Jan Marini Skin Research
2535
Kao USA Inc.
3333
Kernel Medical
1375
Laboratoires Filorga
3375
LC Cell
3287
Lipotec USA Inc.
1013
Medicol USA
1032
Mentholatum Co., The
3515
Merz3015
Nelly De Vuyst Derme & Co.
3261
MAPS
CLOTHING
COSMETICS & SKIN CARE
NeoStrata Co. Inc.
1539
Neutrogena2505
NIA241290
OCuSOFTSkin Care
3260
Ontos Inc.
1011
Palmer’s2969
PCA Skin
1253
Person & Covey
1668
PhotoMedex2135
PhytoCeuticals Inc.
3163
Pierre Fabre USA
3041
Precision Medical Devices LLC
1287
Procter & Gamble
2231
PSI/Vanicream Skin Care
2127
Quintessence Skin Science
3130
Revision Skincare
1241
Sciton1819
Sebamed USA
3286
Sente3567
Sesderma1313
SESHA Skin Therapy
3410
Shantel Medical Supply
2623
SILAB3486
Sinclair Pharma
2989
SkinGen International Inc.
1020
Sun Products
2741
Symbio LLC
3406
Topix Pharmaceuticals Inc.
2019
Unilever2835
XTETIC2975
Young Pharmaceuticals Inc.
1553
ZO Skin Health Inc.
2069
EXHIBIT HALL
5CC (5-Continent-Congress)
2079
American Board of Dermatology
3134
American Society for Dermatologic
Surgery2426
American Society for Mohs Surgery
2723
Brazilian Society for Dermatological
Surgery2475
Coalition of Skin Diseases
2735
Dermatology Foundation
3310
Euro-Asian Association of
Dermatovenerologists1021
European Academy of Dermatology
and Venereology
0001
International Society of Dermatology
3313
JAMA Network, The
3405
Locks of Love Inc.
1308
Mayo Clinic
1193
Mothers TBaby Pregnancy Studies
conducted by OTIS
1329
NIAMS2327
Skin Cancer Foundation, The
3221
Skin Disease Education Foundation
1771
Society of Dermatology Physician
Assistants3315
Solutionreach3528
VisualDx3544
West-TeleVox Solutions
1619
EDUCATION
ASSOCIATIONS, FOUNDATIONS,
& MEDICAL SOCIETIES
EXPLORE THE EXHIBIT HALL
Data current as of Feb. 1, 2017.
MARKET RESEARCH
HRA Healthcare Research & Analytics
Mayo Clinic
1116
1193
MEDICAL EQUIPMENT
& SUPPLIES
eClinicalWorks1877
EZDerm LLC
1005
Henry Schein
1274
MedCo Data
3368
Modernizing Medicine Inc.
2665
Nextech2417
NextGen Healthcare
3519
SanSoleil...Sun Care You Can Wear...
1593
LABORATORY SERVICES
Aurora Diagnostics
1041
Castle Biosciences Inc.
1110
D-Path Dermatopathology
3359
Dermpath Diagnostics
1353
Dermpath Lab of Central States
3327
FibroTx LLC
1170
Henry Schein
1274
Hill Top Research
1831
Mayo Clinic
1193
Miraca Life Sciences
2575
Myriad Genetic Laboratories Inc.
1052
ProPath Dermatopathology
2027
StrataDx1961
TKL Research
1065
West-TeleVox Solutions
1619
LASER & LASER SUPPLIES
Accurate Mfg. Inc.
3271
Aerolase1521
Alma Lasers
2461
Asclepion Laser Technologies
1533
Beijing Sincoheren S&T Development
Co., Ltd.
3458
Beijing Syntech Laser Co. Ltd.
3074
Bios SRL
1390
BTL1133
Caliber Imaging & Diagnostics
1866
Cobalt Medical Supply Inc.
1115
Cutera2527
Cynosure1439
44
Experience AAD in Orlando
DEKA Medical
1469
Delasco1505
Ellipse Inc.
1023
Emvera Technologies LLC
1978
Erchonia Corp.
1953
EunSung Global Corp.
3169
Fotona Lasers
1105
HairMax-Lexington International
1675
Henry Schein
1274
Hironic Co. Ltd.
1288
ILOODA Co. Ltd.
1187
Innovative Optics Laser Eye Protection 2326
LASERING SRL
3321
Laservision1130
Light Age Inc.
1433
LightScalpel3504
Lumenis2541
Lutronic2867
Medicol USA
1032
NewSurg1008
NoIR LaserShields
1327
Oculo-Plastik Inc.
1118
Oxygenetix Institute Inc.
1875
Perigee1581
PhotoMedex2135
Quanta USA
3063
Ra Medical Systems Inc.
2567
Rohrer Aesthetics LLC
2791
Sciton1819
SharpLight Technologies Ltd.
3314
Syneron Candela
2953
ThermoTek Inc.
2175
Tiemann-Bernsco2405
Venus Concept USA Inc.
1121
VivoSight1475
Vydence Medical
1031
Zimmer Medizin Systems
1361
3Gen Inc./DermLite
2635
Accurate Mfg. Inc.
3271
AccuVein1070
Advanced Rad Solutions
1058
Advanced Technology Laser Co. Ltd.
3192
Agnes formerly Gowoonsesang
Cosmetics1265
Anthony Products/Gio Pelle
3305
Bellaire Industry/Mesopen
2977
Biodermis
2431, 3293
Bios SRL
1390
Caliber Imaging & Diagnostics
1866
CNH Pillow Inc.
3219
Cobalt Medical Supply Inc.
1115
Cutera2527
Delasco1505
DermLink Inc.
2581
Dino-Lite Scopes (BigC)
1575
Envy Medical
1219
EunSung Global Corp.
3169
Haircheck3423
Heine USA Ltd.
3161
Henry Schein
1274
Hironic Co. Ltd.
1288
ILOODA Co. Ltd.
1187
Medicol USA
1032
Mercedes Medical
3269
Midmark Corp.
2727
Miramar Labs Inc.
1035
OCuSOFTSkin Care
3260
PerfAction Technologies
3089
Robbins Instruments
1304
SciBase1120
Sensus Healthcare
2275
SurgiTel/General Scientific Corp.
2271
ThermoTek Inc.
2175
Ultralite Enterprises Inc.
2530
VivoSight1475
Xoft-a subsidiary of iCAD Inc.
3413
ZELTIQ1231
Zimmer Medizin Systems
1361
MEDICAL LIGHTING
EQUIPMENT
Anthony Products/Gio Pelle
3305
Bios SRL
1390
Cobalt Medical Supply Inc.
1115
Delasco1505
Designs for Vision Inc.
2078
Heine USA Ltd.
3161
Henry Schein
1274
JILIN PROVINCE KING LASER
TECHNOLOGY CO. LTD.
2886
Medicol USA
1032
Microsurgery Instruments Inc.
2536
Midmark Corp.
2727
MTI Inc.
3343
Robbins Instruments
1304
SanSoleil...Sun Care You Can Wear...
1593
While every effort is made to ensure the accuracy of data within this publication,
the publisher cannot be held responsible for errors or omissions.
EXPLORE THE EXHIBIT HALL
Data current as of Feb. 1, 2017.
OFFICE EQUIPMENT
& SUPPLIES
OTHER
EXHIBIT HALL
MAPS
CITY GUIDE
PHARMACEUTICAL
AbbVie
2053, 2441
Accredo2178
Actelion Pharmaceuticals US
2664
Allergan2253
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
aad.org 45
NOTES
21st Century Oncology
3530
Aclaris Therapeutics, Inc
3526
Action Bag Company
1766
Adako USA
3187
Advalight1679
Allied Powers LLC
3389
Allina Health
3588
Alphaeon Corporation
1666
American College of Phlebology
3491
AMP Medical Products, LLC
3412
Anne Arundel Dermatology, P.A.
3391
AnteAGE MD by Cellese
1081
Anutra Medical
3558
AP Medesthetics, Inc/VeinGogh
3493
Ascentium Capital LLC
1036
Asembia, LLC
1062
Aubio Life Sciences
3386
Bako Integrated Physician Solutions
1128
Baylor Scott & White Health
1567
Biofrontera, Inc.
3579
Biogenix Skin Sciences
1186
Biologica Technologies
1040
Biomed Diagnostics
3388
BioPharmX3390
Boehringer Ingelheim Pharmaceuticals,
Inc3527
Brava Pharma Sales
1778
Capillus, LLC
2683
CarePath Diagnostics
1768
Carismed GmbH
1071
Centura Pharmaceuticals, Inc
1064
Cipher Pharmaceuticals Inc.
1683
Collagen P.I.N.
1688
ContextMedia Health
1075
Corrona LLC
1676
Cortex Technology Aps
2622
Cosmofrance Inc.
3553
CryoProbe1054
Crystal Clear Digital Marketing
3508
Cutanea Life Sciences, Inc
2889
Cynova Laboratories
1183
DANA3492
DefenAge1286
Derma Faith, LLC
3575
Novartis Pharmaceuticals
Corporation
1627, 1635, 1937
Novella Clinical
1367
Novoxel Ltd
1080
Nutrafol1012
NY LASER OUTLET
1016
Omni Bioceutical Innovations
3381
Omnilux3559
Otto Trading Inc
1027, 1270
PatientPoint1014
Payspan Inc.
1084
Peninsula Medical
3191
Perimed Inc.
2379
Philips Respironics
3533
PRIME Journal
1030
ProCell Therapies
3570
Proinnovera GmbH
1091
Promius Pharma
1461
Promoitalia Group S.P.A.
1386
Psoria-Shield Inc.
1068
Refine USA
2482
Regeneron/Sanofi3175
RegimenMD, LLC
1266
Restoration Robotics
3239
Riverchase Dermatology
3591
Rose Micro Solutions 1126, 1930, 3445, 2064
Samumed LLC
3537
Sanford Health
3267
Sawgio, LLC
2880
Scar Heal
2174
Schweiger Dermatology Group
3523
SCS Direct Inc.
3513
Sebela Pharmaceuticals Inc.
3365
Shenzhen GSD Tech Co., Ltd
1278
Skin1017
SkinCeuticals1653
Sterilis LLC
3571
Stratpharma Switzerland
1182
Sun Protection Zone
3031
Suneva Medical
1667
Swiss-American Manufacturing &
Product Development
2834
Tender Corporation
1293
Teoxane Laboratories
1088
Tergus Pharma, LLC
3564
Theradome, Inc.
3557
Thermi3081
Tizo by Fallene, Ltd
1719
Total Clinical Trial Management
3590
Under Skin
2722
United Skin Specialists
3487
Unity Point Health-Methodist Proctor
1589
University of Florida Health Pathology
Laboratorie3489
Viveve, Inc
3465
Viviscal Professional
1082
WON TECH Co, Ltd
2883
Zero Gravity
1087, 3586
Zocular3469
EDUCATION
Accurate Mfg. Inc.
3271
Brymill Cryogenic Systems
2226
Cobalt Medical Supply Inc.
1115
DermaSweep2075
Envy Medical
1219
Henry Schein
1274
Hill Laboratories Co.
3427
Infinity Massage Chairs
3488
MTI Inc.
3343
taberna pro medicum
2227
Tiemann-Bernsco2405
Zimmer Medizin Systems
1361
Dermablend1960
DermapenWorld-Equipmed USA
2583
Dermatology Associates
3460
Dermatology Solutions Group
1788
DermOne LLC
1056
DermoScan GmbH
1377
DermTech2276
Dermwise3541
Dr. Marder Skincare
3583
DRE Medical Inc
3464
Eclipse Aesthetics. LLC
2875
Elekta3509
Emirates Dermatology Society
1770
EndyMed Medical Ltd.
2981
eRelevance Corp
1029
eTreat Medical Diagnostics
1086
Feel Good, Inc.
1076
Feel Good, Inc.
3585
FIGS1281
FineMec Co, Ltd
1169
Focus Medical
2775
Gensco1175
GlitterTots1180
Grand Aespio Inc.
3471
Guangzhou Huafei Tongda Technology
Co., Ltd
1289
Hankins Consulting
1066
Hans Biomed USA, Inc.
1078
Hansderma3518
Healio Dermatology
1090
Hidrex USA
3414
Hill Dermaceuticals, Inc.
1426
HydroPeptide2483
Hy-Tape International
1019
Iagnosis Inc./DermatologistOnCall
3363
Ibero Latin American College
of Dermatology/CILAD
1689
IFC SA
1381
Irmat Pharmacy
3459
Janssen Biotech, Inc.
3005
Johnson & Johnson Consumer Inc
2805
Journey Medical Corporation
3462
JP Medical Publisher
1044
La Roche-Posay
1661
Laseroptek Co., LTD.
3481
LIFTLAB Skin Regeneration
2787
Lilly USA, LLC
3435, 3545
LIPSMART1074
MartiDerm1060
Mastocytosis Society, Inc., The
1291
Mayne Pharma
1481
MCV Physicians-VCU Health
1693
md:ceuticals3387
MDRejuvena, Inc.
3505
MEDWEB1366
Melanoma Foundation of NE/
Brightguard3589
Mesoestetic SL
2680
MetaOptima Technology Inc.
2684
MoleSafe1774
Nanbu Plastics Co, Ltd
1282
NeoGraft3520
New Medical Technology, Inc.
1974
NEWPONG CO., LTD
3581
NovaCutis, Inc.
1577
WELCOME
SharpLight Technologies Ltd.
3314
Syris Scientific
3404
Tiemann-Bernsco2405
UVBIOTEK1591
EXPLORE THE EXHIBIT HALL
Amgen Inc.
2553
Aqua Pharmaceuticals
1339
Aquavit Pharmaceuticals Inc.
2381
AzaClear3566
Bayer2041
bioskin GmbH
1261
Blaine Labs Inc.
3416
Celgene Corp.
1053
Chemistry Rx
2884
Chemotechnique Diagnostics/
Dormer Laboratories
1662
Cobalt Medical Supply Inc.
1115
Crown Laboratories Inc.
2435
Cu-Tech1213
Delasco1505
Dow Development Laboratories
3408
ELON Hair, Nails & Skin
3188
Exeltis USA
3531
Ferndale Healthcare Inc.
2319
Galderma Laboratories, LP
1605
Genentech, a Member of the Roche
Group1305
Henry Schein
1274
Innovaderm Research
1165
ISDIN
2389, 2489
LEO Pharma Inc.
2827, 3211
Medimetriks Pharmaceuticals
1207
Merz3015
Mission Pharmacal Co.
1975
MolluscumRx.1006
Mylan Inc.
3563
OCuSOFTSkin Care
3260
Ontos Inc.
1011
Perrigo3264
Pfizer Inc.
2589
Regen Lab
3407
SmartPractice2823
Stiefel, a GSK company
1389
Sun Pharma
3127
Symbio LLC
3406
TKL Research
1065
Valeant Pharmaceuticals North America
LLC2005
PHOTOGRAPHIC EQUIPMENT
& IMAGING SERVICES
3Gen Inc./DermLite
2635
Canfield Scientific
1927
DermLink Inc.
2581
Dino-Lite Scopes (BigC)
1575
Fotofinder Systems Inc.
1969
Henry Schein
1274
Horus-Adamo SRL
1177
Medicol USA
1032
Mylan Inc.
3563
Quantificare2474
SanSoleil...Sun Care You Can Wear...
1593
STRATA Skin Sciences
2035
PHOTOTHERAPY SUPPLIES
& EQUIPMENT
Beijing Sincoheren S&T Development
Co. Ltd.
3458
Daavlin3153
Delasco1505
46
Experience AAD in Orlando
Data current as of Feb. 1, 2017.
Hironic Co. Ltd.
1288
Kernel Medical
1375
National Biological Corp.
2453
Ra Medical Systems Inc.
2567
Sciton1819
SharpLight Technologies Ltd.
3314
UVBIOTEK1591
PRACTICE MANAGEMENT
ILOODA Co. Ltd.
1187
JAMA Network, The
3405
Journal of Clinical and Aesthetic
Dermatology2565
Karger Publishers
1205
McGraw-Hill Education
3291
Medesthetics Magazine
2785
New Beauty Magazine
1331
NIAMS2327
Practical Dermatology
3062
SanovaWorks (including JDD)
3320
Skin Cancer Foundation, The
3221
Vivacare1671
Wiley2060
Wolters Kluwer
1529
SURGICAL INSTRUMENTS
Advanced Dermatology & Cosmetic
Surgery3215
Advanced MD Inc.
2177
American Society for Dermatologic
Surgery2426
Bank of America Practice Solutions
1264
CareCredit1127
Compulink Business Systems Inc.
2675
CPa Medical Billing
2971
DermLink Inc.
2581
DermResources LLC
2370
Forefront Dermatology
2781
Group Health Physicians
3318
Henry Schein
1274
Integrated Dermatology Group
2767, 3022
Kaiser Permanente
3035
KCD Medical
1966
MedCo Data
3368
MJD Patient Comm/TopDocs.com
2523
NextGen Healthcare
3519
Officite1674
Riverchase Dermatology
3591
Skin & Cancer Associates/
Advanced Dermatology Mgmt
2963
West-TeleVox Solutions
1619
Acuderm2219
AD Surgical
1692
Anthony Products/Gio Pelle
3305
Bovie Medical
2371
Brymill Cryogenic Systems
2226
Cobalt Medical Supply Inc.
1115
Delasco1505
Designs for Vision Inc.
2078
Ellis Instruments
1626
Hayden Medical Instruments
1870
Henry Schein
1274
Hironic Co. Ltd.
1288
JILIN PROVINCE KING LASER
TECHNOLOGY CO. LTD.
2886
Mercedes Medical
3269
Microsurgery Instruments Inc.
2536
Robbins Instruments
1304
Tiemann-Bernsco2405
PUBLISHING & EDUCATIONAL
MATERIALS
Aesthetic Guide, The
1335
American Society for Dermatologic
Surgery2426
CRC Press - Taylor & Francis
1563
Cutis & Cosmetic Dermatology
1767
Derm1012923
Dermatologist, The
2822
Dermatology News
1769
Dermatology Times
1527
DermLink Inc.
2581
Elsevier3205
While every effort is made to ensure the accuracy of data within this publication,
the publisher cannot be held responsible for errors or omissions.
Now Approved!
Connect • the • dots to learn more
Entrance to
convention hall
AAD food court
at booth #2589
PP-CRI-USA-0200 © 2017 Pfizer Inc. All rights reserved. Printed in USA/January 2017
MAPS HELP YOU FIND YOUR WAY
CONVENTION CENTER
FLOOR PLANS
LEVEL 4
ORANGE COUNTY CONVENTION CENTER,
WEST BUILDING
LEVEL 3
48
Experience AAD in Orlando
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
MAPS HELP YOU FIND YOUR WAY
WELCOME
LEVEL 2
EDUCATION
EXHIBIT HALL
E
MAPS
CITY GUIDE
LEVEL 1
NOTES
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
aad.org 49
MAPS HELP YOU FIND YOUR WAY
HYATT REGENCY ORLANDO
FLOOR PLANS
RECREATION LEVEL
WINTER
PARK
BREAKOUT
ROOMS 49-53
GARDEN TERRACE
TENNIS
COURT
WINTER
PARK 54
ORCHID ROOM
VERANDAH
TERRACE
POOLSIDE BAR
POOL DECK
MEZZANINE LEVEL
TERRACE POOL
H A L LW AY TO
GU E S
TRO
COLUMBIA
BREAKOUT
ROOMS
OM
S
BOARDROOM
DISCOVERY
BREAKOUT ROOMS
COLUMBIA
BREAKOUT ROOMS
DISCOVERY
BREAKOUT ROOMS
CHALLENGER BREAKOUT ROOMS
LOWER L EVEL
FITNESS
CENTER
SALON
OPEN TO BALLROOMS BELOW
HOTEL
REGISTRATION
ROCKS
REGENCY LOBBY
ENTRANCE
COFFEE
ETCETERA
CONCIERGE
i
i
B-LINE DINER
FIORENZO‘S PDR
LOBBY BAR
CAR RENTAL
CONVENTION
ENTRANCE
FIORENZO ITALIAN
STEAKHOUSE
INTERNATIONAL LOBBY
ENTRANCE
POOL LEVEL
CONVENTION LEVEL
COCONUTS POOLSIDE
BAR & GRILL
FLORIDA
BALLROOM
THE SPA
GROTTO POOL
URBAN
TIDE
50
Experience AAD in Orlando
ORLANDO
BALLROOM
C
B
A
D
E
F
PLAZA INTERNATIONAL
BALLROOM
G
H
K
L
J
M
I
N
REGISTRATION
COUNTERS
GULF / BUSINESS CENTER / ATLANTIC
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
MAPS HELP YOU FIND YOUR WAY
WELCOME
KEY
EDUCATION
Restrooms
Escalator
Stairway
Elevator
i Information
$ ATM
EXHIBIT HALL
BAYHILL
BREAKOUT ROOMS
ACCESS VIA ESCALATOR
FROM CONVENTION LEVEL
WALKWAY TO
CONVENTION
CENTER
N/S BUILDING
OPEN TO
REGENCY BALLROOM
BELOW
CORAL
SPRING
BARREL
SPRING
Z
PEACOCK
MANATEE SPRING
SPRING
MAPS
E/W BUILDING
ROCK
SPRING
Y
WINDERMERE
BALLROOM
X
CITY GUIDE
W
CELEBRATION
BREAKOUT ROOMS
O
V
REGENCY BALLROOM
P
R
Q
S
U
T
S
RAINBOW
SPRING
SILVER
SPRING
REGENCY
EXPRESS
For the most current, up-to-date information, go to aad.org/AM17 or download the AAD Meeting Mobile App.
NOTES
BLUE
SPRING
aad.org 51
DISCOVER ORLANDO
Fun facts about
ORLANDO
The nickname for the
city of Orlando is “THE
CITY BEAUTIFUL”
More than 2,000
LAKES, SPRINGS
AND RIVERS
for water activities
More than 5,100 restaurants and bars
Orlando is the second most
POPULAR TRAVEL
DESTINATION in the U.S.
(First is Las Vegas)
More than 11
destination SPAS;
168 GOLF COURSES
More than 50 UPSCALE
RESTAURANTS within
10-mile radius of Orlando
Convention Center
Voted “TOP 10
BEST WINE TRAVEL
DESTINATIONS” (2015)
12 versatile SHOPPING
MALL/OUTLET CENTERS
are within a 20-minute radius
Average temperature in March is approximately
78 DEGREES
More than 95 ATTRACTIONS
around the city. It would take
approximately 67 eight-hour days
to visit all entertaining offerings.
More than 55 MILLION
people from around the world
visit every year
52
Experience AAD in Orlando
LOWEST AVERAGE
AIRFARE among top 50
airports (Orlando
International Airport)
21 FITNESS TRAILS
for biking and
walking
DISCOVER ORLANDO
WELCOME
Safety tips
Airport safety
Keep in mind that you’ll want to add extra
time if you are returning a rental car or riding
a shuttle that stops at multiple hotels and
airport terminals. Also, don’t wait until you
arrive at the airport to check in. The majority
of airlines offer online check-in 24 hours
prior to departure.
Protect yourself
Several dining and transportation
options can be accessed using
mobile apps.
You can start by downloading
the Visit Orlando app on Google
Play or in the App Store, or go to
visitorlando.com.
TRANSPORTATION APPS
Make getting around town a snap
with these transportation services.
•Curb: gocurb.com
•Lyft: lyft.com/cities/orlando
•Uber: uberestimate.com/prices/
Orlando/
DINING APPS
Check out menus and make
reservations for dinner.
• Open Table: opentable.com/
orlando-restaurants
• restaurant.com
Stay connected to
AAD through
SOCIAL MEDIA.
The Academy has merged its Twitter accounts
into a single one-stop-shop for all things AAD.
CITY GUIDE
AAD HAS A NEW TWITTER
ACCOUNT.
MAPS
• Remove your Annual Meeting badge
when you are outside the Orange County
Convention Center.
• Walk, ride, or jog with a partner.
• Avoid dark, isolated places — don’t walk
or park in these areas.
Are you looking for options
to have a great time or get
around town while you’re
in Orlando?
EXHIBIT HALL
The Transportation Security Administration
advises attendees to arrive a minimum of 90
minutes before domestic flight departures,
which gives you the time needed to check
in for your flight, check your baggage, go
through security screening, and board your
flight. Airlines typically begin boarding 30
minutes before flights depart.
• Be alert, look around, and be aware of
your surroundings.
• Keep at least one hand free, so avoid
wearing headphones or talking on your
smartphone.
• Have your taxi driver wait and watch until
you enter the convention center, your
hotel, or a restaurant.
• On public transportation, try to use the
busiest, best-lit stop possible when you get
on and off a train or bus. When riding on a
train or bus, sit near the driver or operator.
• After dark, tell family or friends when to
expect you and how you will be traveling.
• When at a bar, never lose sight of your drink.
• Have your hotel key or car keys out and
ready to use.
• Follow your instincts. If you feel
threatened, go to the nearest open business
or store. Call 9-1-1 immediately.
• Always lock the front door or patio door
when inside a hotel room and before leaving.
Use the safety chain/lock for security.
• Never open the hotel room door unless you
know who is there. If you did not call for
the service offered by the person at the door,
call hotel security or the front desk to see if
they have sent someone to your room.
EDUCATION
Safety is a top priority any time you travel.
Follow these common sense reminders to
stay aware while in Orlando.
TRAVEL APPS MAKE
GETTING AROUND EASY
Follow us @AADmember.
LIKE AAD ON FACEBOOK.
Stay updated with Academy news and info
during — and after — the Annual Meeting.
NOTES
Visit facebook.com/AADmember.
aad.org 53
in
W
Oxf ord Rd
a nch Rd
Rd
Lee
N Goldenrod Rd
W Smith St
W Wa s hington St
E South St
E And e rson St
ORLANDO
W Gore St
Inter
Bl
Hein
an
tzelm
NOTES
Tpk
17
a g an
a Pky
92
ld Re
417
Florida
ntral
Gr e e n ewa y
Ce
Central Florida Greenewa
y
R o na
536
vd
527
Town Center Blv d
Dr
S Semoran Blvd
a
nal D
natio
irque Du SoleilDowntown Disney
551
Rd
rb e e
ethe
WW
423
rS
5
1
se
eR
d
Bl
to
os
S Access Rd
Internati
o
Turkey Lake Rd
n ge B
lossom
Trl
S Ora
Centr al
Flori
d a P ky
2
co
S Ora
nge
Ave
S Kirkman Rd
Bruton Blvd
l an
dR
d
Vin
e
W Taft Vineland Rd
Martin Anderson E x p y
Na r
a Vista
E Landstreet Rd
W Landstreet Rd
Bee Line Expy
527
528
➤
5
rtin
Ma
xpy
rson E
Ande
J etport Dr
CITY GUIDE
ng Pky
You
Bee Line Expy
Beach Line
Mccoy Rd
Sand Lake Rd
Tradeport Dr
S Jo h n
d
ORANGE
COUNTY
CONVENTION
CENTER
4
MAPS
482
BELLE ISLE
Rd
ee
o ss
W Sand Lake Rd
Seaworld
Adventure Park
vd
rco
pk
e
3
35
417
Na
nT
n
4
Hoffner Ave
W Oak Ridge Rd
ga
r
al D
3
Restaurant
locations are shown
ist
eV
in green.
Le
506
441
ea
4
6
Pershing Ave
EDGEWOOD
dR
nal
Ro
1
Universal
Studios
Florida
436
Attraction locations
are shown
Pershing Ave in
Ave
Gatlinblue.
o
W Holden Ave
551
552
Trl
S Apopka Vin eland Rd
roy Rd
C on
Vineland Rd
435
Dr S
nal
W Kaley St
92
408
ee
S Econlockhatc h
Conroy Windermere Rd
d
dR
S Ferncreek Ave
527
ve
S Oran ge A
435
Lb Mc l e
E Robinson St
526
S Goldenrod Rd
Rd
S Conway Rd
Hempel Ave
rde n
Ga
E Co
John Cheney Hwy
EXHIBIT HALL
Ol
526
r
nt e
d Wi
Bennet Rd
Mercy Dr
408
Map shows
locations of
attractions and
restaurants listed
on pages
56-59.
50
S Ivey Ln
Good Homes Rd
st Expy
East-We
N Semoran Blvd
N Jo h n Young Pky
W Colonial Dr
Corrine Dr
4
ersity Blvd
EDUCATION
416
Virginia Dr
U ni v
Rd
WINTER PARK
424
438
436
Fors y t h
2
W Fairbanks Ave
423
426
Ave
Aloma
N Dean Rd
438
Eatonville
N Pine Hills Rd
Howell B r
Temple Dr
441
Clarco
na
O coee Rd
Dodd R d
Rose Ave
Lakeville Rd
Blvd
Maitland
Kennedy Blvd
N Hiawassee Rd
o ran
Clarke Rd
S em
Beg gs Rd
Sem
inol
e
S Wymore Rd
WELCOME
d
Silver Star Rd
lvd
W Maitla n d B
17
terna
tio
Rd
Red Bug Lake Rd
LOCATOR MAP
ee
u ena Vista
92
427
414
431
439
17
Altamonte
Springs
Maitland Bl vd
424
Rd
mere
DISCOVER ORLANDO
Rd
Palm Spring
amonte Dr
E Alt
Attractions and restaurants
435
otha
L ake Dr
Casselberry
il l a
l
Tr
aR
rcon
Cla
Sheeler Ave
Blo
ss
om
ter Springs Blvd
Se mino
la Bl
vd
Tus ka w
ge
lvd
aB
ran
Se m o ran Blv
d
436
Bear Lake Rd
SO
Douglas Ave
E Semoran Blvd
Ap
opk
Mccormick Rd
Montgomery Rd
N
Apopka
417
aad.org 55
EXPERIENCE ORLANDO
There’s so much to do in and around
Courtesy of the Morse Museum of American Art, Winter Park, Florida
ORLANDO
Use the list at the right
as a guide to exploring
what Central Florida has
to offer. Whether you’re
looking for attractions
for your accompanying
family or wanting to
explore on your own
after the Annual Meeting
is over, there’s plenty
from which to choose.
56
Experience AAD in Orlando
1
Boggy Creek Airboat Rides
Address: 2001 E. Southport Road,
Kissimmee, Florida
Phone: (407) 344-9550
URL: bcairboats.com
Hours: 9 a.m.-5:30 p.m. daily
Strap in for this unique experience as you
skim across the Central Florida Everglades
on an airboat. Boggy Creek Airboat Rides
offer several tour experiences. Perhaps you’ll
want to take an hour-long daytime tour where
your certified, expert captain will guide your
airboat past tall grass and cypress trees. Be
on the lookout for wildlife! Or maybe you’d
rather try the adrenaline rush of the Night
Expedition where you never know what’s
around the corner. On each type of tour,
though, there’s a good chance you’ll see an
alligator or two.
The Charles Hosmer Morse
Museum of American Art
2
Address: 445 N. Park Ave., Winter Park,
Florida
Phone: (407) 645-5311
URL: morsemuseum.org
Hours: Tuesday-Thursday, Saturday:
9:30 a.m-4 p.m; Friday: 9:30 a.m.-8 p.m.;
Sunday: 1-4 p.m.
The Charles Hosmer Morse Museum of
American Art features American decorative
art from the mid 19th century to the early
20th century. However, the majority of the
museum is devoted to the works of Louis
Comfort Tiffany. The Tiffany Chapel exhibit
features works he created for the 1893
World’s Columbian Exposition in Chicago.
The Laurelton Hall exhibit pays homage to
the artist’s home on Long Island. Though the
actual Laurelton Hall was destroyed by fire in
1957, this exhibit showcases nearly 200 items
that were rescued from the destruction.
EXPERIENCE ORLANDO
WELCOME
This bustling city offers more than theme parks.
EDUCATION
Credit: Discovery Cove
EXHIBIT HALL
Coca-Cola Orlando Eye
Address: 8401 International Drive
Phone: (866) 228-6438
URL: officialorlandoeye.com
Hours: Sunday-Thursday: 10 a.m.-10 p.m.;
Friday-Saturday: 10 a.m.-12 a.m.
Discovery Cove
Address: 600 Discovery Cove Way
Phone: (407) 513-4600
URL: discoverycove.com
Hours: 9 a.m.-5 p.m. daily
Discovery Cove provides once-in-a-lifetime
experiences as you come face-to-face with
amazing underwater sealife. Plan to spend
the day at this unique water playground
that offers several unique experiences. For
example, Dolphin Lagoon offers you a
one-on-one dolphin encounter — you can
even swim with these friendly creatures. At
Freshwater Oasis, the newest attraction, wade
through the water-filled trails to meet otters
and other freshwater critters. Perhaps you’ll
want to end your day with a leisurely float
down the Wind-Away River. Reservations are
required to visit this park.
World of Chocolate Museum
& Café
5
Address: 11701 International Drive
URL: wocorlando.com
Hours: Monday-Friday: 11 a.m.-7 p.m.;
Saturday and Sunday: 10:30 a.m.-7 p.m.
aad.org 57
NOTES
Those with a sweet tooth will enjoy a tour
of The World of Chocolate Museum & Café.
Take a museum tour and learn about cacao,
the origins of chocolate, how chocolate is
made, and the history of this sweet treat.
The sculpture area of the museum features
25 solid chocolate sculptures of some of the
world’s most notable landmarks, including
the Great Wall of China, the Eiffel Tower,
and Mt. Rushmore. Round out the tour with
a stop in the tasting room, offering chocolate
samples from around the world. Tours last
approximately one hour and spaces are
available on a first come, first serve basis.
CITY GUIDE
Climb aboard the Coca-Cola Orlando Eye
and experience the city from above. Soaring
400 feet above the ground, this observation
wheel gives riders a bird’s-eye view of
Orlando and surrounding area. On a clear
day, you can even see Cape Canaveral —
almost 60 miles away — on Florida’s eastern
coast. Rides, here known as flights, take
place in air-conditioned capsules and last for
approximately 23 minutes. Save $5 when you
purchase your ticket online.
4
MAPS
3
DISCOVER ORLANDO
Here’s a sampling of
WHERE TO EAT
Eddie V’s Prime Seafood
and Steak
1
2
Highball & Harvest
3
Address: 4012 Central Florida Parkway
Phone: (407) 206-2400
URL: ritzcarlton.com/en/hotels/florida/
orlando/dining
Cuisine: Southern cuisine
Hours: Breakfast: 6:30-11 a.m. daily; Lunch:
11:30 a.m.-2:30 p.m. daily; Dinner: 5:3010:30 p.m.; Lounge: 12-11 p.m.
Price: $$$
Distance from convention center: 2.5 miles
Address: 7488 W. Sand Lake Road
Phone: (407) 355-3011
URL: eddiev.com
Cuisine: Steak and seafood
Hours: Sunday-Thursday: 4-11 p.m.;
Friday-Saturday: 4 p.m.-12 a.m.
Price: $$$
Distance from convention center: 1.9 miles
“Man cannot live by music, wine and fine
dining alone. But it’s worth exploring.”
Or so says the website of Eddie V’s. If you’re
looking for a happy hour spot to unwind
after a day at the meeting, stop by Eddie
V’s. Happy hour — featuring live jazz in
the Lounge — occurs here daily from 4 to 7
p.m. If you’re wanting to meet colleagues for
dinner, Eddie V’s is known for its seafood,
and fish from all varieties are delivered to
the restaurant daily from around the world.
Try an appetizer of Maine lobster tacos made
with handmade tortillas or a main course
of Alaskan sablefish, Chilean sea bass or
Norwegian salmon. For turf lovers, the menu
offers several meat options, including lamb
chops and New York strip steaks.
This family-owned and operated restaurant
serves up traditional Ethiopian fare. The
menu spans the gamut. Start with an
appetizer, perhaps azifa, a combination of
lentils, onions, green peppers, and lemon
juice mixed with Ethiopian mustard. Entrees
appeal to meat lovers and vegetarians,
alike. Choose from the chicken/doro wat,
which is chicken stewed in red pepper sauce
flavored with house spices and served with
a hard-boiled egg. Or maybe try yellow split
peas cooked with onions, garlic, and green
peppers. But be aware; there’s no silverware
here. Instead, customers use injera, a
sourdough flatbread that is torn into pieces
and used to pick up your food.
Courtesy of The Ritz-Carlton Orlando, Grande Lakes
Located in the Ritz-Carlton, Highball &
Harvest features a modern spin on Southerninspired favorites, with an emphasis on local
ingredients. The restaurants draws from nine
local farms and even grows its own produce
and herbs in the on-site 7,000-square-foot
garden at Whisper Creek Farm. The breakfast
menu features sweet potato waffles, avocado
toast, and the traditional Southern favorite of
chicken and waffles. For lunch, choose from
Seminole pumpkin soup, pimento grilled
cheese, or a grouper sandwich. Dinner offers
NY strip, duck and dumplings and, as a
vegan option, cauliflower steak. The lounge
menu features cocktails, all infused with
seasonal fruits and herbs.
Nile Ethiopian Restaurant
Address: 7048 International Drive
Phone: (407) 354-0026
Cuisine: Ethiopian
Hours: Monday-Friday: 5-10 p.m.;
Saturday and Sunday: 4-11 p.m.
Price: $$
Distance from convention center: 2 miles
58
Experience AAD in Orlando
PRICE GUIDE $: Under $10
$$: $11-30
$$$: $31-60
DISCOVER ORLANDO
WELCOME
Restaurants to consider while you’re in town.
Seito Sushi & New Japanese
5
Sofrito Latin Café
Modern, Japanese, and artisan are words that
best describe both the food and ambiance at
Seito Sushi & New Japanese. Here, chefs
transform fresh ingredients into coastal
Asian cuisine every day. The menu offers
beverages, such as sake and Japanese
whiskey, as well as traditional Asian dinner
favorites. The menu features a variety:
seafood, sushi, noodles, meats, soups, and
salads. Happy hour runs from 5 to 6:30 p.m.
daily and offers $2 off all rolls and $2 off
all small plates, along with assorted drink
specials. Come enjoy the sophisticated,
contemporary ambience with friends and
colleagues.
The atmosphere at Sofrito Latin Café invites you
to feel at home, and the menu features cuisine
from several Latin countries: Argentina, Chile,
Colombia, Cuba, the Dominican Republic,
Puerto Rico, Peru, and Venezuela. Some menu
highlights include the patacon sandwich from
Venezuela, made with two fried green plantains,
shredded beef or roast pork, and a cilantro-garlic
sauce. For entrees, perhaps you’ll want to try
pollo a la brasa from Peru, a chicken cooked
with fresh herbs; or churrasco from Argentina, a
skirt steak topped with chimichurri sauce. Round
out your meal with a sweet Nutella empanada.
While visiting Sofrito, browse the community
bookcase where you’ll find a variety of board
game and Hispanic books. It’s all part of making
you feel right at home.
Tabla Restaurant
Address: 5827 Caravan Court
Phone: (407) 248-9400
URL: tablacuisine.com
Cuisine: Indian, Chinese, Thai
Hours: Tuesday-Sunday: Dinner: 6-11 p.m.
Price: $$
Distance from convention center: 4.6 miles
Tabla Restaurant serves up authentic Indian/
Pakistani, Chinese, and Thai cuisines. The
flavors, combined with the restaurant’s
modern presentation of dishes, earned
it Orlando’s Best Indian Restaurant by
TripAdvisor in 2016. The menu offers classic
dishes, as well as twists on regional favorites.
Featured dishes include tandoori, Indian
curry, and rice and noodles. Specifically,
choose from Aloo Tikki Chat, which are
potato patties flavored with Indian spices and
served with yogurt and chick peas. Or maybe
you’d rather try lemon coriander soup, a
mixture of lemongrass, piquant chilies, and
sliced mushrooms. Round out your meal
with a delicious dessert, such as pineapple
kheer, or rasmalai, described as a cheesecake
without a crust. Reservations are accepted.
MAPS
Address: 8607 Palm Parkway
Phone: (407) 778-4205
URL: sofritocafe.com
Cuisine: Latin food
Hours: Sunday-Thursday: 11 a.m.-9 p.m.;
Friday-Saturday: 11 a.m.-10 p.m.
Price: $$
Distance from convention center: 3.9 miles
EXHIBIT HALL
Address: 8031 Turkey Lake Road
Phone: (407) 248-8888
URL: seitosushi.com
Cuisine: Sushi
Hours: Sunday-Thursday: 5-10 p.m.;
Friday-Saturday: 5-11 p.m.
Price: $$
Distance from convention center: 1.6 miles
6
EDUCATION
4
CITY GUIDE
Credit: Rob Bartlett
NOTES
aad.org 59
A PLACE FOR YOUR NOTES
NOTES
Record notes from sessions you attend. Make a list of exhibitors to visit in the Exhibit Hall. Keep
track of phone numbers of new professionals you meet. Use this space to keep track of it all.
60
Experience AAD in Orlando
A PLACE FOR YOUR NOTES
WELCOME
EDUCATION
EXHIBIT HALL
MAPS
CITY GUIDE
NOTES
aad.org 61
A PLACE FOR YOUR NOTES
62
Experience AAD in Orlando
A PLACE FOR YOUR NOTES
WELCOME
EDUCATION
EXHIBIT HALL
MAPS
CITY GUIDE
NOTES
aad.org 63
A PLACE FOR YOUR NOTES
Advertiser index
Aclaris Therapeutics, Inc
Allergan
Aubio Life Sciences
Beiersdorf, Inc.
Carilion Clinic
Celgene Corporation
Episciences, Inc.
15
7, 8, 16-17, 36-37, inside back cover
31
5
15
Cover tip, 24-25, 26
Inside front cover
Image Skincare
Modernizing Medicine Inc.
Pfizer
Riverchase Dermatology
Valeant Pharmaceuticals North America LLC
ZO SKIN HEALTH
1
Back cover
3, 22, 47
46
41, 42
30
This advertiser index is provided for the reader’s convenience and is not part of the advertising contract. While every attempt is made to provide accurate
information, the publisher cannot be held responsible for errors or omissions.
64
Experience AAD in Orlando
Available in pharmacies soon
Visit
Allergan booth
2253
to learn more
Register for samples at rhofadehcp.com
© 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners. rhofadehcp.com RHO104192 01/17 163541
Value-based care is here.
Are you prepared?
A leader in dermatology-specific solutions that provide
everything you need to achieve MIPS success.
*2016 Black Book Research
Cloud
|
Mobile
|
Touch
EMA™ - THE #1-RATED DERMATOLOGY-SPECIFIC EHR SYSTEM*
Stop by
BOOTH
#
2665
PRACTICE MANAGEMENT
REVENUE CYCLE MANAGEMENT
ANALYTICS
TELEHEALTH
PATHOLOGY
modmed.com | 561.235.7501